Appendix — Contact Lens Manufacturers Ass'n v. Food & Drug Administration

Supreme Court brief1986

Ask Donna

What actually matters in this document.

Text

85-980 ~~ | ccs we

No.

vo | Supreme Court, us.

7):

a

oy

tr

os:

IN THE

Supreme Court of the United States

OctoBerR TERM, 1985

Contact LENS MANUFACTURERS ASSOCIATION,

Petitioner,

Vv.

Foop AND Drua ADMINISTRATION OF THE DEPARTMENT

OF HEALTH AND HuMAN SERVICES,

Respondent.

On Petition for Writ of Certiorari to the United States

Court of Appeals for the District of Columbia Circuit

APPENDIX TO

PETITION FOR WRIT OF CERTIORARI

DANIEL J. MANELLI

Counsel of Record

Epwarp A. SCALLET

THOMPSON & MITCHELL

1120 Vermont Avenue, N.W.

Suite 1000

Washington, D.C. 20005

(202) 857-0350

Attorneys for

Contact Lens Manufacturers

Association

ee sar eR UA EL CT ET TELA

PRESS OF BYRON S. ADAMS, WASHINGTON, D.C. (202) 347-8203

(i)

TABLE OF CONTENTS

Aprenpix A Page

July 9, 1985 Judgment of the United States Court

of Appeals for the District of Columbia Circuit .. la

Appenpix B

July 9, 1985 Opinion of the United States Court

of Appeals for the District of Columbia Circuit .. 2a

Appenpix C

September 10, 1985 Order of the United States

Court of Appeals for the District of Columbia

Circuit Denying Petition for Rehearing ....... 25a

Aprenpix D

Department of Health and Human Services, Food

and Drug Administration, 21 CFR 886 [Docket

No. 82N-0180], Reclassification of Daily Wear

Spherical Contact Lenses Consisting of Rigid Gas

Permeable Plastic Materials, Withdrawal of Pro-

OU ME PEL aida Cheese ck cub nen ecibnee snes ce 26a

Appenpix E

Department of Health and Human Services, Food

and Drug Administration, 21 CFR 886 [Docket

No. 82N-0180], Proposed Reclassification of Daily

Wear Spherical Contact Lenses Consisting of

Rigid Gas Permeable Plastic Materials ........ 106a

Appenpix F

Department of Health and Human Services, Food

and Drug Administration, 21 CFR 886 [Docket

No. 82N-0180], Notice of Intent: Reclassification

of Daily Wear Spherical Contact Lenses Con-

sisting Principally of Hydroxyethylmethacrylate

(HEMA) or Rigid Plastic Materials ........... 145a

(ii)

Taste or Corrents continued

Appenpix G Page

Department of Health and Human Services, Food

and Drug Administration, 21 CFR 886 [Docket

No. 82N-0180], Proposed Reclassification of Daily

Wear Spherical Contact Lenses Consisting of

Rigid Gas Permeable Plastic Materials; Reopen-

ing of Comment Period; Advance Notice of Public

SUES Gvcc cn cou ccccupnceeccteahecesuaswenues 149a

Apprenpix H

Statutes and Regulations Involved ............. 156a

Medical Device Amendments .............. 156a

DE ONE. Vc én bates eve chu dswasseucns 156a

SE WEE: Nac cacdusncexsckdeewseaenne 167a

SE. Sawai ek ok be kw oh 00 ddb0asecbaskeans 184a

la

APPENDIX A

UNITED STATES COURT OF APPEALS

FOR THE DISTRICT OF COLUMBIA CIRCUIT

Sepremser Term, 1984

No. 84-1025

Contact Lens MANUFACTURERS ASSOCIATION,

Petitioner

v.

Foop & Druc ADMINISTRATION OF THE

DEPARTMENT OF HeaLtH aND Human SERvICEs,

Respondent

Petition for Review of an Order of the

Food & Drug Administration

Before: Rostnson, Chief Judge, WaLp and Grnssure,

Circuit Judges.

[Filed July 9, 1985. George A. Fisher, Clerk]

JUDGMENT

This cause came on to be heard on the petition for review

of an order of the Food & Drug Administration, and was

argued by counsel. On consideration thereof, it is

ORDERED and ADJUDGED, by this Court, that the

petition for review herein is dismissed and the challenged

decision is hereby affirmed, in accordance with the Opinion

for the Court filed herein this date.

Per Curiam

For The Court

/s/ Georce A. FisHER

George A. Fisher

Clerk

Date: July 9, 1985

Opinion for the Court filed by Circuit Judge Ginsburg.

APPENDIX B

United States Court of Appeals

FOR THE DISTRICT OF COLUMBIA CIRCUIT

No. 84-1025

CONTACT LENS MANUFACTURERS ASSOCIATION, PETITIONER

Vv.

Foop & DruG ADMINISTRATION OF THE DEPARTMENT OF

HEALTH AND HUMAN SERVICES, RESPONDENT

Petition for Review of an Order of the

Food & Drug Administration

Argued February 26, 1985

Decided July 9, 1985

' Daniel J. Manelli, with whom Edward A. Scallet was

on the brief, for petitioner.

Beverly Sherman Nash, Attorney, Department of Jus-

tice, Richard K. Willard, Acting Assistant Attorney Gen-

eral, J. Patrick Glynn, Margaret A. Cotter, Mark H.

Gallant, Attorneys, Department of Justice and Michael

M. Landa, Attorney, Food and Drug Administration.

Before: ROBINSON, Chief Judge, WALD and GINSBURG,

Circuit Judges.

3a

Opinion for the Court filed by Circuit Judge GINSBURG.

GINSBURG, Circuit Judge: In 1938, Congress armed

the Food and Drug Administration (FDA) with author-

ity to prevent the marketing of hazardous drugs. By the

mid-1970’s, however, it had become apparent that the

legislature’s delineation of the FDA’s domain was too

narrow to enable the agency to protect the public from

some of the most dangerous health care products. Mind-

ful of recent misfortunes involving faulty pacemakers

and the Dalkon Shield, Congress enacted the Medical

Device Amendments of 1976 (Amendments or statute),

Pub. L. No. 94-295, 90 Stat. 539 (codified at 21 U.S.C.

$§ 360c-360k (1982)), thereby extending the FDA’s pre-

market surveillance field beyond drugs to medical devices.

This case, one of first impression, involves the FDA’s

administration of the Amendments.

Congress’ new prescription for the FDA divided the

world of medical devices into three classes, according to

the degree of regulation thought necessary to provide

reasonable assurance of each device’s “safety and effec-

tiveness.” Class I encompassed devices whose safety and

effectiveness could be reasonably assured by “general con-

trols” set out in various sections of the Food, Drug, and

Cosmetic Act, 21 U.S.C. §§ 301-392 (1982). Class II

covered devices that posed somewhat greater risks; de-

vices placed in this category would be subject to “per-

formance standards” in addition to the residual general

controls. Class III was to obtain devices (1) whose

safety and effectiveness could not be reasonably assured

by any combination of general controls and performance

standards, and (2) whose purported purpose was to aid

in supporting or sustaining human life or preventing its

impairment, or whose availability presented “a potential

unreasonable risk of illness or injury.” No device con-

signed to class III could be sold to the general public

until, through a costly and time-consuming process, it

had gained the FDA’s “premarket approval.” See § 360c

(a) (1) td.

4a

Congress itself was not positioned to determine the

appropriate classification of every medical device then in

existence or yet to be invented; nor could it describe the

statutory categories with sufficient precision to ensure

that each device would simply fall into the proper class

of its own accord. The legislators therefore charged the

FDA with the task of implementing the Amendments,

and thus of essaying judgments appropriate to ensure

safe and effective medical devices without stifling innova-

tive technology. See H.R. Rep. No. 853, 94th Cong., 2d

Sess. 12-13 (1976) [hereinafter cited as House Report).

Congress drew several initial bright lines, however,

that significantly affected the classification process.

“(Devices of a type introduced or delivered for intro-

duction into interstate commerce for commercial distri-

bution” before the date of the Amendments’ enactment

were to remain entirely outside the classification scheme

until the FDA decided where to place them. See 21

U.S.C. § 360¢(c) (3); General Provisions and Classifica-

tion of 119 Devices, 47 Fed. Reg. 3694, 3694 (1982)

{hereinafter cited as Mass Classification Proposal]. De-

vices introduced after the date of enactment, by contrast,

would rank in class III unless shown to belong to a non-

class-III family of devices and to be “substantially equiv-

alent” to a particular, already-marketed device within

that family. See 21 U.S.C. § 360c(f) (1) (A); 21 C.F.R.

$ 860.1384 (1984). Moreover, under provisions labeled

“transitional,” class III ranking automatically attached

to “[a]ny device intended for human use . . . which the

[FDA] in a notice published in the Federal Register be-

fore the enactment date has declared to be a new drug.”

21 U.S.C. § 8360j(/)(1)(E). The FDA could later re-

classify any device that, for whatever reason, had been

“overclassified,” but this remedy required a proffer of

“new information,” id. § 360c(e)—or, as the FDA for-

mulated the standard, “valid scientific evidence” of

safety and effectiveness. 21 C.F.R. §§ 860.7, .123(a) (6).

5a

The instant petition concerns the first attempt ever

to reclassify a medical device committed to class III by

the Amendments’ “transitional provisions.” Contact Lens

Manufacturers Association (CLMA) challenges the FDA’s

withdrawal of the agency’s own proposal to transfer cer-

tain rigid gas permeable (RGP) contact lenses from

class III to class I. 48 Fed. Reg. 56,778 (1983). Claim-

ing that RGP lenses (and hence, RGP lens manufactur-

ers) have suffered disparate treatment in relation to

other medical devices (indeed, other contact lenses),

CLMA urges that “something has gone very wrong

here.” Brief of Petitioner at 2. We conclude, however,

that CLMA’s travails are attributable to the ivtricacies

of the legislation Congress ordered, and to the broad

administrative discretion Congress conferred upon the

FDA. Because our review satisfies us that the FDA has

permissibly exercised its considerable discretion in this

case, we affirm the agency’s action.

I.

Contact lenses consisting almost entirely of polymethyl-

methacrylate (PMMA)—‘“hard” lenses—have been mar-

keted in the United States since the early 1950’s. See

Regulatory Policy and Proposed Rulemaking for Market-

ing Contact Lenses, 40 Fed. Reg. 44,844, 44,845 (1975)

{hereinafter cited as New Drug Notice]. Because the

public’s pre-Amendments experience with PMMA lenses

was broad ard substantially injury-free, see id., these

lenses will remain outside the Amendments’ classifica-

tion scheme until the FDA formally decides where to

place them. See supra p. 3. That decision has not yet

been made; three years ago, however, the FDA proposed

to regulate PMMA lenses as class II devices. See Mass

Classification Proposal, 47 Fed. Reg. at 3736.

Hydroxyethylmethacrylate (HEMA) lenses—‘“soft”

lenses—are a more recent development. The FDA first

approved a HEMA lens in 1971. See 47 Fed. Reg. 53,411,

6a

43,415 (1982). In September 1975, citing their relative

novelty, the FDA announced that HEMA lenses—indeed

all lenses “other than those consisting [almost wholly] of

PMMA”—had been and would continue to be regarded

as “new drugs”:

This decision to regulate such contact lenses under

the new drug provisions of the Federal Food, Drug,

and Cosmetic Act was based on a recognition that

new plastic materials that had not been shown to be

safe and effective were being introduced for use in

the manufacture of contact lenses. The introduction

of these new materials led to new lens design and

use, new manufacturing methods, and new methods

for lens care. The Food and Drug Administration

is concerned that the use of these contact lenses may

result in serious eye damage if the new material of

which they are composed is unsafe for use in the

eye, if the user cannot feasibly care for the lenses,

or if the highly complex procedures for the manu-

facture of these lenses are not carefully controlled

to assure a product of uniform quality.

New Drug Notice, 40 Fed. Reg. at 44,845. This an-

nouncement rendered HEMA lenses class III devices un-

der the Amendments’ “transitional provisions.” See su-

pra p. 3; cf. infra note 3 (rejection of reclassification

proposal).

The product at issue in this case is said to combine

attractive features of both lens types described above.

“RGP lenses” (like “PMMA lenses” or “HEMA lenses”)

is a generic term that indicates no single mix of polymers

or manufacturing process; but all lenses properly called

RGP share certain salient characteristics. The ideal RGP

lens permits both the superior visual acuity attainable

with a hard lens and the “direct transmission of oxygen

to corneal tissue” that the hard lens regrettably prevents.

See 47 Fed. Reg. 53,402, 53,406 (1982) [hereinafter

cited as Reclassification Proposal]. Nearly a million peo-

7a

ple in the United States wore RGP lenses in 1982. /d.'

As of 1975, however, RGP lenses, like soft lenses, were

comparatively new and untested; since enactment of the

Amendments the FDA has regarded RGP lenses as

“transitional” class III devices by reason of the same

September 1975 Federal Register announcement that re-

sulted in placement of HEMA lenses in the class III

category. See supra p. 5; infra pp. 11-12.

Consequently, before a manufacturer can market a

particular RGP lens to the public, the manufacturer

must demonstrate the safety and effectiveness of that

lens convincingly enough to gain the FDA's premarket

approval. “[(I]}n effect,” the manufacturer must obtain

“a license to market the device.” Brief for Respondent

at 5 n.6. (If RGP lenses were class I devices, the manu-

facturer would be required to make the showing CLMA

regards as less burdensome that the lens was “sub-

stantially equivalent” to another RGP lens already on

the market. See 21 U.S.C. § 360c(f)(1)(A) (1982); supra

p. 3. But see infra pp. 17-19.) The expense of obtaining

a class III device ticense—“estimated at $750,000-

$1,000,000 (over and above development costs),” Brief

of Petitioner at 11, the bulk of which goes to clinical

investigation—constitutes a significant barrier to entry.

Not surprisingly, the first and largest of several manu-

facturers to surmount the premarket-approval hurdle,

Syntex Ophthalmics, commands a dominant share of the

market for RGP lenses. CLMA barely disguises its sug-

gestion that Syntex is implicated in the FDA's decision

to hold RGP lenses within the class III regime.

That decision did not follow a steady path. In March

1981 CLMA petitioned the FDA to reclassify RGP lenses

from class III to class II. Pursuant to 21 U.S.C. § 360c¢(b)

1 Counsel for CLMA, demonstrating warm zeal for his

client, informed the court in opening lines of oral argument

that he and his co-counsel were themselves satisfied wearers

of RGP lenses.

8a

(1982), the FDA referred the petition to an expert

advisory committee, the Ophthalmic Section of the Oph-

thalmic; Ear, Nose, and Throat; and Dental Devices

Panel, which recommended the following month that the

petition be granted on the condition that CLMA submit

additional materials. In November 1981 the FDA an-

nounced that although CLMA’s upgraded submissions

continued to be inadequate, “CLMA’s objectives are

meritorious,” and therefore the FDA intended to adopt

the reclassification proposal as the agency’s own. See 46

Fed. Reg. 57,648 (1981). The FDA promised to publish

a formal proposal in a future issue of the Federal Reg-

ister; meanwhile, the agency solicited comment on var-

ious economic issues that appeared unrelated to the

lenses’ safety and effectiveness. See id. at 57,648-49.

In November 1982, a year after the FDA’s initial indi-

cation of interest, the reclassification proposal emerged.”

“Based on a careful review of new, publicly available,

valid scientific evidence,” the proposal stated, “FDA has

tentatively concluded that . . . certain [RGP lenses]

should be reclassified into class I.” Reclassification Pro-

posal, 47 Fed. Reg. at 53,404. The proposal was limited

to spherical lenses consisting of cellulose acetate butyrate

(CAB) or polyacrylate-silicone. Jd. But departing from

CLMA’s original request for class II designation, the

proposal recommended reclassification down to class I.

Although the FDA then “believe[d] that sufficient in-

formation exist[ed] to establish a [class II performance]

standard,” the agency also felt that safety and effective-

ness could be adequately assured without such a stand-

ard. Id. at 53,405-06. The proposal extensively and

2In the interim, FDA represent: ives had been questioned

by members of a House subcommittee about the “rather un-

usual” delay. FDA Oversight: Medical Devices: Hearing

Before the Subcomm. on Oversight and Investigations of the

House Comm. on Energy and Commerce, 97th Cong., 2d Sess. -

3 (1982) (remarks of Rep. Whittaker) ; see id. at 29-34, 95-

96, 104-06.

9a

favorably discussed the clinical data cited by reclassifica-

tion proponents. Nevertheless, the FDA invited comment

on a range of issues including the following:

1. Do the data presented in this proposal consti-

tute sufficient “valid scientific evidence’ of safety

and effectiveness to support reclassification of each

(currently] marketed lens [and any lens that might

be created] consisting of CAB or polyacrylate-

silicone?

4. Does specifying the materials of which the

lenses proposed for reclassification are principally

composed adequately identify the lenses for the pur-

pose of reclassification?

Id. at 53,410.

The uncertainty intimated by these questions soon be-

came palpable. On December 10, 1982, the FDA extended

the comment period thirty days, till January 26, 1983.

47 Fed. Reg. 55,497 (1982). On April 15, 1983, the

comment period was reopened. 48 Fed. Reg. 16,293

(1983). A public hearing was held on May 26, 1983,

followed by yet another fifteen-day comment period. See

48 Fed. Reg. 18,836 (1983). Finally, on December 23,

1988, CLMA’s once high expectations for the RGP pro-

posal ended: the FDA repudiated its “tentative con-

clusions” and withdrew its reclassification proposal al-

together. 48 Fed. Reg. 56,778 (1983).°

’CLMA’s petition to reclassify HEMA lenses underwent a

parallel odyssey and met an identical fate. Finding CLMA’s

January 1981 proposal deficient, the FDA itself took up the

reclassification cause. 46 Fed. Reg. 57,648 (1981). A year

later, the FDA formulated an official proposal to transfer

HEMA lenses from class III to class I, and asked for com-

ments. 47 Fed. Reg. 53,411 (1982). After enlarging the

comment period, reopening it, holding a public hearing, and

receiving more comments, the FDA killed the proposal on

April 24, 1984. 49 Fed. Reg. 17,523 (1984).

10a

The FDA attributed its changed view to “comments

and oral and written testimony that required it to re-

evaluate the evidence upon which it relied in the pro-

posal, and to evaluate additional information.” Jd. at

56,781. First, the agency explained, various commenters

had demonstrated that the clinical studies cited as proof

of the safety and effectiveness of CAB and polyacrylate-

silicone lenses * then on the market did not, after all, add

up to “valid scientific evidence.” Jd. at 56,780. Second,

even if the studies did constitute such evidence, they were

“insufficient to justify reclassification” because they

“fail[ed] to establish the safety and effectiveness of

[RGP] lenses as a generic type of device.” Jd. Given

the countless conceivable combinations of “polymer formu-

lation and manufacturing processes,” and the correspond-

ing variations in lenses’ “nontoxicity, biocompatibility,

[and] light transmission,” the FDA could not conclude

that mere membership in the family of “RGP lenses”

clinched any particular lens’ safety and effectiveness. Jd.

The FDA thus determined that no reclassification of

RGP lenses could provide reasonable assurance of safety

and effectiveness: class I status was not feasible because

the FDA could not determine whether a new lens was

“substantially equivalent” to an already-marketed lens

without securing a wealth of detailed information about

both lenses’ composition and manufacture; and class II

status was not in order because, even if such informa-

tion could be gathered for the purpose of establishing a

“performance standard’ and measuring new lenses

against it, conformity with the standard would not guar-

antee that a lens would function safely and effectively in

the human eye. Jd. at 56,780-81. “In short, FDA learned

that at this stage in [RGP lens] development, there is no

4The petition for review concerns only the FDA’s treat-

ment of polyacrylate-silicone lenses. Brief of Petitioner at 8

n.4. Accordingly, the term “RGP lenses,” as henceforth used

in this opinion, denotes lenses made of polyacrylate-silicone.

lla

substitute for clinical trials [i.e., class III status] to

provide reasonable assurance of the safety and effective-

ness of these lenses.” Jd. at 56,781.

CLMA complains, in petitioning for review, that the

FDA has disregarded a medical consensus favoring re-

classification and has rendered insensible the requirement

of “valid scientific evidence.” We recognize substantial

merit in CLMA’s argument that RGP lenses should not

be locked within so tight a regulatory regime. Nonethe-

less, we cannot disturb the FDA’s decision. The agency

acted within an area of its expertise, it ruled in a man-

ner at least arguably consistent with the statutory scheme,

and it considered the matter in a detailed, adequately

reasoned fashion. We therefore defer to the agency and

affirm its judgment. See Chevron, U.S.A., Inc. v. Natural

Resources Defense Council, 104 S. Ct. 2778, 2782-83

(1984) ; Rettig v. Pension Benefit Guaranty Corp., 744

F.2d 138, 151 (D.C. Cir. 1984) (quoting Chevron).

II.

We address at the outset CLMA arguments that the

entire reclassification project was misconceived because

RGP lenses were never class III devices to begin with.

FDA’s responses * indicate, correctly as we see the regu-

° The FDA initially asserts that we lack “jurisdiction” to

consider these arguments “because CLMA did not raise them

in the rulemaking proceeding.” Brief for Respondent at 51.

If the arguments were placed before the agency, however, we

may review them even if CLMA was not the presenter. See

Toy Mfrs. of Am. v. Consumer Prod. Safety Comm’n, 630

F.2d 70, 73 n.5 (2d Cir. 1980); see also Lorion v. United

States NRC, 712 F.2d 1472, 1474 (D.C. Cir. 1983) (court

reviews “only those contentions subjected to agency scrutiny

during the administrative process”), rev’d on other grounds

sub nom. Florida Power & Light Co. v. Iorion, 105 S. Ct.

1598 (1985). Inspection of the challenged withdrawal notice

reveals that the arguments in question, or substantially

similar ones, were in fact rehearsed before the agency.

12a

latory scheme, the limitations of the categories Congress

established.

First, CLMA maintains that RGP lenses are not prop-

erly drawn into the web of the Amendments’ “transi-

tional provisions.” The provision in question assigns to

class III “[{a]ny device intended for human use...

which the [FDA] in a notice published in the Federal

Register before the enactment date has declared to be a

new drug.” 21 U.S.C. § 360j(/) (1) (E) (1982). The

FDA identifies its September 1975 announcement of

“Regulatory Policy and Proposed Rulemaking for Market-

ing Contact Lenses,” see supra p. 5, as the relevant

notice. CLMA characterizes that notice as a preliminary

announcement, merely a proposal for a declaration of

new drug status, not the declaration itself. Brief of

Petitioner at 52.

The asserted distinction between declaration and pro-

posed declaration, in the context of the Amendments,

lacks persuasive force. The statute requires only notice—

not, for example, notice tested in the crucible of public

comment. Further, to the extent that CLMA’s argument

rests not on statutory interpretation but on construction

of the September 1975 declaration as tentative, we can-

not agree. The announcement conveys the distinct im-

pression that regulation of non-PMMA lenses as “new

drugs” was a fait accompli, at that stage missing only

a formal seal:

The policy of the [FDA] of regarding all contact

lenses other than those consisting [almost] entirely

of PMMA as new drugs has been publicized and is

generally known to contact lens manufacturers... .

Although the Agency’s enforcement policy regard-

ing contact lenses has previously been publicized,

this policy is not set forth in Title 21 of the Code

of Federal Regulations. Accordingly, the Commis-

sioner of Food and Drugs has concluded that, for-

l3a

mally to advise the public, this regulatory policy

should be promulgated as a regulation and codified

in Title 21, C.F.R.

New Drug Notice, 40 Fed. Reg. at 44,845.°

Second, CLMA contends that RGP lenses are “custom

devices” as that term is defined in the Amendments, and

are on that account exempt from the classification scheme.

A “custom device” is

any device which, in order to comply with the order

of an individual physician or dentist . . . necessarily

deviates from an otherwise applicable performance

standard or [premarket approval] requirement .. .

if (1) the device is not generally available in finished

*CLMA also suggests that the September 1975 announce-

ment was inadequate in that it “did not mention polyacrylate-

silicone lenses. The only polymers specifically mentioned were

CAB ..., polycarbonate, silicone, and HEMA, types of con-

tact lenses which are readily distinguishable from poly-

acrylate silicone.” Brief of Petitioner at 53. But the list to

which CLMA refers did not purport to be exclusive. It merely

cited examples of contact lens materials about whose safety

and effectiveness the FDA was particularly concerned—ma-

terials “other than PMMA.” New Drug Notice, 40 Fed. Reg.

at 44,845. Polyacrylate-silicone, CLL.MA does not deny, is a

further example of such material.

Our view that RGP lenses were covered by the September

1975 announcement, and are therefore properly ranked as

class III devices under the Amendments’ transitional provi-

sions, suffices to answer CLMA’s further contention that

these lenses merit less stringent regulation because of their

“substantial equivalen[ce]” to PMMA lenses. See Brief of

Petitioner at 61-63. The 1975 announcement, and subsequent

FDA glosses on it, foreclose any argument that RGP lenses

and lenses made almost entirely of PMMA instance the same

“type of device”; thus, there is no occasion for a substantial-

equivalence determination. See 21 U.S.C. § 360c(f) (1) (A)

(1982); cf. 21 C.F.-R. § 860.84 (1984) (distinguishing, for

classification purposes, between (1) devices substantially

equivalent to pre-Amendments devices, and (2) devices regu-

lated as “new drugs”’).

l4a

form for purchase or for dispensing upon prescrip-

tion and is not offered through labeling or advertis-

ing by the manufacturer, importer, or distributor

thereof for commercial distribution, and (2) such

device—

(A) (i) is intended for use by an individual

patient named in such order of such physician

or dentist . . . and is to be made in a specific

form for such patient, [and]

(B) is not generally available to or generally

used by other physicians or dentists ....

21 U.S.C. § 360j(b) (1982). The definition is an eyeful,

but essentially it appears to reflect a commonsense con-

gressional judgment that the design and composition of

certain medical devices are so individualized that sub-

jecting them to the usual regulatory controls would be

impractical (and a complementary judgment that such

particularly constructed devices are so closely monitored

by the prescribing physician that stringent regulation

might well be excessive). The House Report on the

Amendments lists as examples of custom devices “ortho-

pedic and other prosthetic devices, dental devices, and

specially-designed orthopedic footwear”; the same report

cautions that invocation of the exemption must be

“limited.” HOUSE REPORT, supra p. 3, at 44.

We are satisfied that the FDA acted reasonably in re-

fusing to accord custom-device status to RGP lenses. It

suffices to observe that the FDA could rationally regard

such lenses as “generally available to or generally used

by other physicians.” CLMA’s argument to the contrary

focuses obsessively on the individual lens ground to a

particular doctor’s specifications; CLMA disregards the

consideration, urged by the FDA, that the statutory

language is most sensibly read as referring to a more or

less inclusive class of devices rather than to any given

exemplar of the class. And even if the relevant question

lda

were whether a specifically prescribed lens was “gen-

erally available to or generally used by other physicians,”

there would be force to the FDA’s contention that any

specimen lens “is merely a variation within an approved

range of powers and anterior and posterior surface con-

tours.” Brief for Respondent at 62. In other words,

prescriptions for all but the most pathological eyes are

likely to be replicated again and again and thus to be

“generally used.” CLMA insists that this construction

of “generally used” could as easily lead to a ruling that

orthopedic shoes are not “custom devices.” But insofar

as the FDA’s conclusion from the logic and language of

the statute appears contrary to the result intimated by

some of the examples of “custom devices” offered in the

legislative history, the FDA has: properly cast its lot

with the former. See, e.g., Eagle-Picher Industries v.

United States EPA, 759 F.2d 922, 929 (D.C. Cir. 1985).

In short, it appears to us from the arguments made

that the premise on which the FDA's initial reclassifica-

tion proposal rested—that RGP lenses are currently class

III devices—is altogether reasonable. The critical ques-

tion that remains is whether the FDA could rationally

refuse to bring its reclassification proposal to fruition.

Il.

The FDA has consistently maintained that proponents

of reclassification assume the burden of demonstrating—

through “publicly available, valid scientific evidence’”—

that the device’s present classification is inappropriate

and that the proposed classification will provide reason-

able assurance of the device’s safety and effectiveness.

See, e.g., 48 Fed. Reg. at 56,779. We cannot fault the

FDA’s assignment of the burden of proof to those seek-

ing to change the status quo. See, e.g., HOUSE REPORT,

supra p. 3, at 40. Thus, CLMA’s claim that maintenance

of class III status for RGP lenses lacks record support,

16a

even if true, is off target. More to the point, CLMA

asserts that the FDA in these proceedings has adopted

an unreasonably strict view of what constitutes “valid

scientific evidence.” Though CLMA presses this argu-

ment with vigor, we are mindful that in such matters

generalist courts see through a glass darkly and should

be especially reluctant to upset an expert agency’s judg-

ment that a party has failed to adduce sufficient scien-

tific proof of safety and effectiveness.

The FDA’s rationale for withdrawing its reclassifica-

tion proposal opens with the rather belated assertion that

nothing in the record establishes the safety and effective-

ness of RGP lenses now on the market. Facets of this

position are unsettling. In justification of its current

stance, the FDA disparaged, see 48 Fed. Reg. at 56,784-

85, the same studies it had once acclaimed, see Reclassifi-

cation Proposal, 47 Fed. Reg. at 53,406-09, and retracted,

see 48 Fed. Reg. at 56,783, its earlier assertion that

“(t]he safety of the device also is shown by the absence

of reports in the literature of serious, irreversible ad-

verse effects on health presented by the device,” see Re-

classification Proposal, 47 Fed. Reg. at 53,405. But the

reclassification proposal specifically asked for comment on

whether “the data . . . constitute sufficient ‘valid scien-

tific evidence.” Jd. at 53,410. We would be denying

the value of notice-and-comment rulemaking were we

to condemn the FDA for altering its outlook on the basis

of submissions it received.

Citing its regulation declaring that “|[i]solated case

reports, random experience, reports lacking sufficient de-

tails to permit scientific evaluation, and unsubstantiated

opinions are not regarded as valid scientific evidence to

show safety or effectiveness,” 21 C.F.R. § 860.7(c) (2)

(1984), the FDA discounted the praises sung by dozens

of “contact lens professionals” who favored reclassifica-

tion and who reported that none of their patients had ever

experienced serious problems with RGP lenses. 48 Fed.

17a

Reg. at 56,786-87. We find the FDA’s categorical be-

littiement of these eyewitness comments somewhat numb-

ing, but we cannot gainsay the FDA’s judgment that

although such testimonials may suffice to disprove safety

and effectiveness, they fail to establish with scientific

rigor the absence of danger. See 21 C.F.R. § 860.7(c) (2).

The FDA’s ultimate resistance to conceding the safety

and effectiveness of lenses now on the market is perhaps

most remarkable because these are the very lenses al-

ready granted premarket approval on the application of

particular manufacturers. The agency's demand for com-

pelling proof on matters presumably demonstrated to it

convincingly by the licensed manufacturers, however, is

a conundrum the statute itself sets up. Under the

Amendments, trade secret information that a manu-

facturer submits to secure premarket approval may not

be cited by the FDA or any third party in aid of re-

classification proposals. 21 U.S.C. § 360j(c), (h) (3)

(1982). Much as in patent law, Congress has determined

that free riding is too high a price to pay for vigorous

competition among medical device manufacturers;? the

FDA is not at liberty to disregard this determination.

Of decisive importance, however, the FDA’s refusal to

reclassify RGP lenses does not stand or fall with the

FDA’s limited-purpose agnosticism about the safety and

effectiveness of lenses currently on the market. Inde

pendently sufficient and far more persuasive is the FDA’s

oo

* As the legislative history explains:

To use trade secret information submitted in connection

with a class III device as the basis for “downgrading” it

into class II status—and thus allowing it to be replicated

by competitors to conform to a standard—would destroy

the originator’s competitive advantage and could serve

to stifle the initiative for innovation.

HOUSE REPORT, supra p. 3, at 50.

18a

determination that all reclassification proposals to date

“inadequately characterize” the class of RGP lenses.

That is, even if the available evidence demonstrates the

safety and effectiveness of lenses already on the market,

this evidence cannot be taken as proof that any RGP

lens a manufacturer might create will meet the statu-

tory requirements; thus, at least for the present, the pre-

market approval process is unavoidable. “[T]he safety

and effectiveness of a contact lens is a function of the

complex interrelationship of material, design, and manu-

facture that results in a unique set of physical, chemical,

mechanical, and optical characteristics.” 48 Fed. Reg. at

56,792. Alter any one of these variables, the FDA now

maintains, and you have a unique new lens whose safety

and effectiveness are unknown and, without thorough

clinical testing, unknowable. To be sure, the reclassifica-

tion proposal described RGP lenses generically in glow-

ing terms: “Contact lenses composed of . . . polyacrylate-

silicone are characterized as chemically and physically

stable under the conditions of their intended use, opti-

cally clear, nontoxic, and nonallergenic.” Reclassification

Proposal, 47 Fed. Reg. at 53,404. But in retrospective

clarification, the FDA explains this statement as the

depiction of a paradigm rather than an assertion that

every potential combination of RGP materials, design,

and manufacture will prove safe and effective.

The inadequacy of generic characterization of RGP

lenses thus emerges as a mainstay of the FDA’s conten-

tion that nothing short of lens-by-lens clinical testing

and premarket approval will ensure safety and effective

ness. If RGP lenses were class I devices, the FDA would

have no firmer basis on which to divine the safety and

effectiveness of new lenses than a ninety-day inquiry into

whether the lenses were “substantially equivalent” to other

lenses already on the market. See 21 U.S.C. § 360(k),

360c(f)(1)(A) (1982); 21 C.F.R. § 807.87 (1984). In

its reclassification proposal, the FDA asserted that such

19a

an inquiry would suffice—provided, however, that the

prospective manufacturer was

prepared to demonstrate substantial equivalence in

terms including, but not limited to, design; composi-

tion; optical transmission (and homogeneity) and

index of refraction; and other physical properties

including oxygen permeability, chemical and physical

stability, tensile and flexural strength; biocompati-

bility, including cytotoxicity, eye irritation, and non-

support of bacterial growth; impurities; leachables;

heavy metal levels; preservative uptake and release;

. . . lens care/cleaning regimen compatibility! ; and

manufacturing process].

Reclassification Proposal, 47 Fed. Reg. at 53,405.

The detail of this checklist suggests that, from the

start, the FDA felt insecure about reclassifying RGP

lenses. Upon withdrawing its proposal, the FDA an-

nounced its tardy recognition that the contemplated sub-

mission would be “indistinguishable”’ from the data re-

quired in a premarket approval application. 48 Fed.

Reg. at 56,790. In other words, on close inspection, the

FDA determined that class I assignment simply was not

feasible. Given the detailed data submission necessary

to find “substantial equivalence,” prospective RGP lens

manufacturers would be put to a burden approaching

that entailed by the premarket approval process. At the

same time, appraising such evidence “on a comparison

basis” rather than for the purpose of “determin[ing] the

safety and effectiveness of a device in the first instance,”

id., would be both difficult and constraining. Not only

would the problem of trade secret information, see supra

p. 16, impede comparative evaluation; in addition, the

exacting character of the comparisons involved might dis-

courage innovation by requiring the manufacturer of a

new RGP lens to demonstrate “substantial equivalence”

almost to the point of patent infringement. See, e.g.,

20a

Joint Appendix (J.A.) at 334 (comments of Dow Corning

Ophthalmics) .*

The FDA’s doubts about generic characterization of

RGP lenses led it to conclude as well that class II “per-

formance standards,” such as those formulated by the

American National Standards Institute, would fail to

provide reasonable assurance of safety and effectiveness.

See 48 Fed. Reg. at 56,791. Although compliance with

such standards may be easy to measure and may attest

to a lens’ physical, chemical, and optical integrity, the

FDA observes that there is no scientifically proven rela-

tionship between fulfillment of the laboratory criteria

and performance in the human eye.

On its face, the proposition that “minor changes in

lens material formulation or manufacturing process can

significantly [and unpredictably] affect the safety and

effectiveness of lenses manufactured from the material,”

id. at 56,780, appears at least plausible. Indeed, a di-

luted form of this proposition—the chance that “there

may conceivably be polymeric combinations within the

category of polyacrylate-silicone which are not suitable

for making RGP lenses”—-strikes CLMA as “self-evident.”

Brief of Petitioner at 47. CLMA’s complaint is that the

imposition of expensive clinical testing requirements on

each new type of RGP lens—requirements to which

fewer than five percent of all medical devices are sub-

ject, see id. at 6 & n.3—is wholly out of proportion to

the lenses’ capacity for mischief.

*In discussing the “substantially equivalent” test, the

Amendments’ legislative history confirms that the FDA is

well within its discretion in declining to attempt comparison

of devices that are disparate in such important respects as

composition or design: “differences between ‘new’ and mar-

keted devices in materials [or] design . . . would have a bear-

ing on the adequacy of information as to a new device's

safety and effectiveness, and such [new] devices should be

automatically classified into class III.” House REPoRt, supra

p. 3, at 36.

2la

Given the record before the FDA, however, the agency

could responsibly conclude that novel RGP lenses pose

“a potential unreasonable risk of illness or injury.” 21

U.S.C. § 360c(a)(1)(C) (1982) (describing conditions

under which FDA may place pre-Amendments device

in class III); see, e.g., J.A. 339 (comments of David M.

Worthen, M.D.); id. at 354, 357 (comments of Syntex

Ophthalmics, Inc.); id. at 381 (comments of Barnes-

Hind/Hydrocurve, Inc.) ; see also Brief for Respondent

at 53-55 (arguing that, in any event, CLMA failed to

demonstrate the nonexistence of such risk). It is true

that companies like Syntex Ophthalmics, whose RGP

lenses had already won premarket approval, were the

principal doomsayers. But their apparent interest does

not render their comment valueless. See National Soft

Drink Association v. Block, 721 F.2d 1348, 1354 (D.C.

Cir. 1983) (“We do not weigh the evidence; we merely

examine the record to see if there is evidence, which if

accepted by the Secretary, supports the determination of

the agency.”).°

*CLMA further contends that the FDA abused its discre

tion by failing to consider the controlled clinical setting in

which contact lenses are prescribed and fitted. The safety and

effectiveness of a device are to be determined, in part, “with

respect to the conditions of use prescribed, recommended,

or suggested in the labeling of the device.” 21 U.S.C.

§ 360c(a)(2)(B) (1982). CLMA argues that RGP lenses

present no risk of irreversible injury; rather, the patient's

eyes simply get a little red, at which point his optometrist or

ophthalmologist orders a different sort of lens. Brief of Peti-

tioner at 33; see Reply Brief of Petitioner at 12 (in this

manner, competition will weed out unsafe and ineffective

lenses without the need for FDA supervision).

The FDA usefully might have supplied a more explicit

t of the context in which RGP lenses are

marketed, and a fuller explanation of why that context does

not obviate the need for strict regulation. Cf. 48 Fed. Reg.

at 56,787-88 (denying that medical supervision justifies en-

largement of reclassification proposal to encompass nonspheri-

cal lens designs about whose safety and effectiveness there is

22a

We are troubled, nonetheless, by the argument that

the FDA’s treatment of RGP lenses, even if internally

logical and supported by several comments in the record,

is impeached by the agency’s action in other dockets.

Comparative sideglances, CLMA contends, demonstrate

graphically that RGP lenses have received an inordi-

nately hard look. For example, in January 1982, the

FDA proposed to classify 119 previously unclassified oph-

thalmic devices already on the market when Congress

passed the Amendments; in that proposal, the FDA de-

scribed “artificial eyes” generically as devices “usually

made of glass or plastic,” without any suggestion that a

more precise specification of materials or manufacturing

processes might be necessary. Mass Classification Pro-

posal, 47 Fed. Reg. at 3724. It may make sense to say

that devices designed for prolonged contact with so

delicate and vital an organ as the living eye merit more

circumspect regulation than do devices that merely stand

in for that organ once it is lost; to the extent that this

proposition is intuitively obvious, the FDA may be for-

given for not stating it. But how does the FDA account

for its proposal, id. at 3736, to regulate PMMA lenses

as class II devices? Is it not myopic for the FDA to

ignore the variations in materials and manufacture of

devices that appear to present risks of the same order

as those posed by RGP lenses—devices that, in fact,

raise the additional problem of depriving the cornea of

oxygen?

The FDA implies that PMMA lenses’ “extensive his-

tory of safe and effective human use” justifies a more

lenient form of regulation. See 48 Fed. Reg. at 56,787.

a “complete lack” of evidence). But CLMA’s argument ap-

pears rooted in a premise the FDA has quite clearly rejected

—that the risks posed by RGP lenses are too inconsequential

to merit prior regulatory restraints. And surely the infamous

histories of the two devices that principally inspired the

Amendments, see supra p. 2, belie the assertion that the

participation of a doctor renders premarket approval un-

necessary.

nse lala

Ye ee eed ~

23a

This response is not altogether satisfactory. Although an

“extensive history of safe and effective human use” may

constitute, or obviate the need for, “valid scientific evi-

dence” of the safety and effectiveness of PMMA lenses

currently on the market,'® it cannot—by the FDA’s own

hypothesis—inform us about lenses that as yet are but

a glimmer in a polymer chemist’s eye. Perhaps the range

of possibilities is narrower, the predictability of results

greater, for PMMA lenses than for RGP lenses. Cf.

48 Fed. Reg. at 56,787 (suggesting “potential significant

differences in . . . uniformity” between PMMA and

RGP lenses). If not, we would be hard-pressed to recon-

cile differential classification of the two devices. See

also J.A. 388 (comments of Precision-Cosmet Co.) (crit-

icizing “the ‘hard lens attitude’ in the industry which

is essentially [that] one will do just as one pleases, since

‘hard’ lenses have never hurt anyone’”’).

But the issue is not ripe for our consideration. The

FDA acts on classification initiatives at a pace fairly

10Tn its proposal to classify 119 ophthalmic devices, for

instance, the FDA validated its advisory panel’s reliance on

essentially anecdotal evidence:

In many cases, the Panel based its recommendations on

Panel members’ personal knowledge of, and clinical ex-

perience with, the devices under review. The Panel

particularly relied upon clinical experience and judgment

when considering a «imple device that had been used

extensively and was accepted widely before the amend-

ments were enacted. ... FDA has determined that

clinical experience and judgment is valid scientific evi-

dence for classifying certain devices.

Mass Classification Proposal, 47 Fed. Reg. at 3696. The

panel’s recommendation regarding PMMA lenses seems to

have been based on the same sort of evidence. See id. at

3736. By the year 2000, therefore, if the FDA follows a

consistent course, we would expect questions about the safety

and effectiveness of lenses already on the market, see supra

pp. 15-16, to pose no continuing impediment to reclassification

of RGP lenses.

24a

described as glacial. The January 1982 proposal to

place PMMA lenses in class II remains only a proposal.

Since that proposal antedates by almost two years the

CLMA-challenged withdrawal of the proposed reclassi-

fication of RGP lenses, we would not be surprised if the

FDA were having second thoughts. We do not prejudge

the appropriate classification of PMMA lenses; we sug-

gest only that, should the FDA ultimately decide to treat

PMMA and RGP lenses differently, we will not feel that

our respect for the agency’s judgment has been vindi-

cated unless the FDA explains why such a distinction is

coherent. In the meantime PMMA lenses continue to be

entirely free of any classification, but that is the way

the statute Congress designed works.

IV.

We are cognizant of the ironies effected by the statute

and the FDA’s initially insecure administration of it. Con-

sidering the difficulty of the assignment Congress entrusted

to the agency, and the respect we owe to the FDA’s

expert judgment, however, we cannot say that the action

we have been asked to review is unlawful. Many of

CLMA’s claims of inequitable treatment are better

addressed to Congress; others are not yet ripe. We hold

simply and only that at this juncture, the FDA has not

been shown to have proceeded without reason or regard

for the statute in withdrawing its proposal to reclassify

RGP lenses. The petition for review is accordingly dis-

missed and the challenged decision is

Affirmed.

ae

25a

APPENDIX C

UNITED STATES COURT OF APPEALS

FOR THE DISTRICT OF COLUMBIA CIRCUIT

SreprEMBER TERM, 1984

No. 84-1025

Contact Lens Manuracturers ASSOCIATION

Vv.

Foop anp Druc ADMINISTRATION OF THE

DepaRTMENT OF HEALTH AND Human SERVICES

[Filed September 10, 1985. George A. Fisher, Clerk]

ORDER

Upon consideration of petitioner’s petition for rehearing,

it is

ORDERED, by the Court, that the petition is denied.

Per Curiam

For Tue Court

Georce A. FisHer, CLERK

By: /s/ Rospert A. BonNER

Robert A. Bonner

Chief Deputy Clerk

26a

APPENDIX D

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

21 CFR Parr 886

[Docket No. 82N-0180]

RECLASSIFICATION OF DAILY WEAR SPHERICAL CON-

TACT LENSES CONSISTING OF RIGID GAS PERMEABLE

MATERIALS; WITHDRAWAL OF PROPOSED RULE

AGENCY: Food and Drug Administration.

ACTION: Withdrawal of proposed rule.

SUMMARY: The Food and Drug Administration (FDA) is

withdrawing its proposed rule to reclassify marketed daily

wear spherical contact lenses consisting of certain rigid

gas permeable plastic materials from class III (premarket

approval) into class I (general controls). FDA has deter-

mined, after providing two opportunities for submission of

comments and evidence, after holding a public hearing fol-

lowed by an additional period for submission of comments

and evidence, and after reconsidering the basis for FDA’s

tentative conclusion that class I would provide reasonable

assurance of the safety and effectiveness of the device,

that there is insufficient new, publicly available, valid scien-

tific evidence to show that the device is safe and effective.

to characterize the device adequately for the purpose of

reclassification, or to demonstrate that either class I or

class II (performance standards) would provide reason-

able assurance of the safety and effectiveness of the device.

Class IIIvis necessary to provide such assurance.

EFFECTIVE DATE: (Insert date of publication in the

FEDERAL REGISTER.)

Nha altace etiam

27a

FOR FURTHER INFORMATION CONTACT:

Albert Van de Griek,

National Center for Devices and Radiological Heaith

(HFK-402),

Food and Drug Administration,

8757 Georgia Ave.,

Silver Spring, MD 29010,

301-427-8162.

SUPPLEMENTARY INFORMATION:

For the convenience of the reader, the following is an

index of the sections throughout this document:

I. History of the Proceedings.

II. Overview of the Basis for FDA’s Decision.

A. Background.

B. Insufficient Evidence of Safety and Effective-

ness.

C. Inadequate Characterization of Materials.

D. Inadequacy of Class I or Class II to Provide

Reasonable Assurance of Safety and Effective-

ness.

E. Need for Clinical Trials.

F. Conclusion.

Il. Analysis of Comments.

Classification.

Identification.

Adequacy of Safety and Effectiveness Data.

Adequacy of Characterization.

Adequacy of General Controls.

Adequacy of Class IT.

Need for Clinical Trials.

. Economic Impact of Reclassification.

Beas IAD>

28a

I. Contact Lens Accessories.

J. Tinted Contact Lenses.

K. Miscellaneous Matters.

IV. References.

I. HISTORY OF THE PROCEEDINGS

In the FEDERAL REGISTER of November 26, 1982

(47 FR 53402), FDA published a proposed rule to re-

classify marketed daily wear spherical contact lenses con-

sisting of certain rigid gas permeable plastic materials

from class III into class I. (For convenience, the lenses

proposed for reclassification are referred to throughout

this document as rigid gas permeable lenses and all other

references to lenses refer to contact lenses.) Interested

persons were given until December 27, 1982, to comment

on the proposal. In the FEDERAL REGISTER of Decem-

ber 10, 1982 (47 FR 55497), FDA extended the comment

period to January 26, 1983. Following a review of the

eomments received during this period, FDA determined

that resolution of complex scientific issues raised by the

comments would be facilitated by reopening the comment

period to receive additional information on certain specific

issues. Therefore, in the FEDERAL REGISTER of April

15, 1983 (48 FR 16293), FDA reopened the comment period

for 30 days. Several requests for a public hearing before

the Commissioner of Food and Drugs were received. In

the FEDERAL REGISTER of April 26, 1983 (48 FR

18836). FDA announced that a public hearing would be

held to afford interested persons an opportunity to present

information and views on the issues involved in the re-

classification proceeding. The hearing, which was held on

Mav 26, 1983. was followed by an additional 15-day com-

ment period to allow ;»cerested persons to submit written

comments on matters raised at the hearing. The comment

- period following the hearing closed on June 10, 1983.

29a

i. OVERVIEW OF THE BASIS FOR FDA’S DECISION

A. Background

Section 513(e) of the Federal Food, Drug, and Cosmetic

Act (the act) (21 U.S.C. 360c(e)) authorizes FDA to re-

classify a device based on ‘‘new information’’ respecting

the device. (See the preamble to the proposed rule (47 FR

53404) for a comprehensive discussion of the meaning of

the term ‘‘new information.’’) The ‘‘new information’’ on

which any reclassification of a device is based is required

to consist of ‘‘valid scientific evidence,’’ as defined in

§ 860.7 of the regulations governing medical device classi-

fication procedures (21 CFR 860.7). FDA relies only upon

such evidence to determine whether there is reasonable

assurance that a device is safe and effective (§ 860.7(c)(1)).

As the agenev explained in the preamble to the final rule

establishing Part 860 (21 CFR Part 860), the purpose of

the Medical Device Amendments of 1976 (Pub. L. 94-295)

(the amendments) is to assure the safety and effectiveness

of medical devices intended for human use and such assur-

ance necessarily demands a high standard of proof (43

FR 32988 ; July 28. 1978).

For the purpose of reclassification, the valid scientific

evidence upon which the agency relies is required to be

publicly available, i.e., may not be based on trade secret

or confidential commercia! information in any premarket

approval application (PMA) for a medical device or on

trade secret or confidential commercial information from

any investigation concerning the safety and effectiveness

of a device (section 520(c) of the act (21 U.S.C. 360j(c)).

Such valid scientific evidence also may not be based upon

the detailed summary of information respecting the safety

and effectiveness of any device for which there is an ap-

proved PMA (section 520(h)(3) of the act) and which

FDA is required to make available to the public upon

issuance of an order approving a PMA (section 520(h) (1)

of the act).

30a

In the preamble to the proposed rule (47 FR 53404),

FDA stated:

To reclassify a device under section 513(e) of the

act, the statute and the regulations require that the

new, publicly available, valid scientific evidence of

safety and effectiveness show (1) why the device

should not remain in its present classification and

(2) that the proposed reclassification will provide rea-

sonable assurance of the safety and effectiveness of

the device. In the case of a device classified in class

III and proposed for reclassification into class I, the

statute and the regulations require such evidence of

safety and effectiveness to show (1) why the device

should not remain in class III and (2) that general

controls will provide reasonable assurance of the safe-

ty and effectiveness of the device.

The general controls are those authorized by or under

sections 501 (adulteration), 502 (misbranding), 510 (regis-

tration, listing, and premarket notification), 516 (banned

devices), 518 (notification and other remedies), 519 (rec-

ords and reports), and 520 (general provisions including

current good manufacturing practice requirements) of the

act (21 U.S.C. 351, 352, 360, 360f, 360h, 350i, and 360j).

In the preamble to the proposed rule, FDA summarized

the data on which the proposed reclassification was based

(47 FR 53406-53409) and tentatively concluded that rigid

gas permeable lenses should be reclassified into class I,

rather than into class IT upon the effective date of a per-

formance standard established under section 514 of the act

(21 U.S.C. 360d) (47 FR 53404). In FDA’s judgment at

that time, the information discussed in the preamble showed

that the device was safe and effective for its intended use.

FDA also believed that the general controls provisions of

the act would be sufficient to provide reasonable assurance

of the safetv and effectiveness of the device. The decision

3la

to propose reclassification into class I, rather than class IT

once a performance standard was established, was based

on FDA’s belief that although sufficient information existed

to establish a standard to provide reasonable assurance of

the safety and effectiveness of rigid gas permeable lenses,

there was no need to establish a performance standard to

provide such assurance.

Issuance of a proposed rule to reclassify a device from

class III into class I under section 513(e) of the act does

not preclude promulgation of a final rule to reclassify the

device into class II, if the evidence warrants such action,

particularly where, as in this proceeding, the preamble to

the proposed rule invited comments on the appropriateness

of reclassification into class II, before or after the estab-

lishment of a performance standard under section 514 of

the act for the device. A class II device is one for which

general controls by themselves are insufficient to provide

reasonable assurance of the safety and effectiveness of the

device. for which there is sufficient information to establish

a performance standard to provide such assurance, and

for which ‘‘it is therefore necessary to establish * * * 9

performance standard under section 514 to provide reason-

able assurance of its safety and effectiveness’’ (section

513(a)(1)(B) of the act; 21 CFR 860.3(c)(2)).

Tn the preamble to the proposed rule (47 FR 53410).

FDA invited comments on several specific issnes inelvding

the following questions:

1. Do the data presented in this proposal constitute

sufficient ‘‘valid scientific evidence’? of safetv and

effectiveness to support reclassification of each mar-

keted lens consisting of CAB or polyacrylate-silicone?

a. If not, what additional publicly available data are

there to support reclassification?

b. If so, are general controls sufficient to provide

reasonable assurance of the safety and effectiveness

of the device?

32a

c. If general controls are not sufficient to provide

reasonable assurance of the safety and effectiveness

of the device, is there sufficient information to estab-

lish a performance standard to provide such assur-

ance?

d. If general controls are not sufficient, and there

is sufficient information to establish a performance

standard to provide reasonable assurance of [the]

safety and effectiveness of the device, is a perform-

ance standard necessary to assure any of the lens

properties or design characteristics that FDA has

identified as ‘‘clinically significant’’ * * * or to protect

against any of the concerns raised in the 1975 notice

declaring as new drugs all contact lenses consisting

of polymers other than PMMA °* * *?

e. Should any reclassification take effect (i) before

or (ii) after such a standard has been established?

3. With respect to the lenses proposed for reclassi-

fication, FDA has limited data on their use for the

correction of hyperopia and in some cases aphakia.

May FDA reclassify a lens for use in the correction

of myopia, hyperopia, and aphakia based solely or

primarily on data showing that the lens is safe and

effective (a) for the correction of myopia? (b) for the

correction of myopia and aphakia?

4. Does specifying the materials of which the lenses

proposed for reclassification are principally composed

adequately identify the lenses for the purpose of re-

classification?

5. * * *, [T]he safety or effectiveness of a specific

rigid gas permeable contact lens is affected by its

specific composition, design, and various other clini-

cally significant properties.

33a

a. Do the data presented in this proposal provide

sufficient ‘‘valid scientific evidence’’ of the safety and

effectiveness of CAB or polyacrylate-silicone lenses

of any specific composition, design, or other charac-

teristic?

b. If the data do not provide this evidence, may the

identified lenses be reclassified because of FDA’s ten-

tative decision that the safety and effectiveness of

composition, design, or other clinically significant

properties of specific lenses can be assured through

premarket notification submissions and substantial

equivalence determinations?

7. - 7

B. Insufficient Evidence of Safety and Effectiveness

In response to question 1 above, a number of comments

presented cogent arguments that the data described in the

preamble to the proposal do not constitute sufficient new,

publicly available. valid scientific evidence (valid scientific

evidence) of safety and effectiveness to support reclassifi-

cation. FDA agrees in general with these comments, which

are discussed in detail in section ITI.C. of this document.

Additional comments in response to question 1.a. and in

response to the April 15, 1983 notice reopening the com-

ment period. in an effort to supply the valid scientific

evidence of safetv and effectiveness required for reclassi-

fication. submitted detailed summaries of a portion of clini-

cal trials conducted on two specific polyacrylate-silicone

contact lenses, and a detailed summary of the preclinical

evaluation of one of the lenses. (No data pertaining to the

safety or effectiveness of cellulose acetate butyrate (CAB)

rigid gas permeable lenses were provided in or submitted

with any comments.) As discussed in paragraph 14 of this

document. serious questions have been raised concerning

the completeness of the submitted data. Even if there were

no such auestions, however, the data merely would serve

to show the safety and effectiveness of two polyacrylate-

34a

silicone lenses characterized only by brand name and made

of unspecified material. Such a showing would be insuffi-

cient to justify reclassification because, among other things,

the information would fail to establish the safety and effec-

tiveness of polyacrylate-silicone lenses as a generic type

of device.

C. Inadequate Characterization of Materials

CAB or polyacrylate-silicone materials that might be

used for manufacturing rigid gas permeable lenses can

consist of thousands of formulations and have a wide vari-

ty of physical and chemical properties. Only a small per-

centage of such materials have the necessary combination

of characteristics of nontoxicity, biocompatibility, light

transmission, and machinability to serve as the basis for

the design and manufacture of safe and effective contact

lenses. Comments from opponents of reclassification argue,

and a comment from one proponent of reclassification

agrees, that minor changes in lens material formulation or

manufacturing process can significantly affect the safety

and effectiveness of lenses manufactured from the material.

A comment opposing reclassification further argues that

although controlled minor changes in a single variable by

a manufacturer can result in predictable changes in safety

and effectiveness, major or multiple changes, or a change

from one manufacturer to another. can result in changes

in the lens’ clinical performance that are not easily pre-

dicted.

FDA agrees with the comments opposing reclassification.

If specific CAB or polyacrylate-silicone lenses had been

shown to be safe and effective by valid scientific evidence

and had been characterized by polymer formulation and

manufacturing processes, such information might have been

sufficient to have allowed comparison, for the purpose of

determining substantive equivalence, with other lenses that

had been shown to be very similar in polymer formulation

and manufacturing process, and, as a result, to have al-

35a

lowed an inference of comparable safety and e*fectiveness

of such other lenses. However, no information about poly-

mer formulation and no information about manufacturing

processes was disclosed in or submitted with any of the

comments, and FDA is prohibited by sections 301(j) and

520(c) of the act (21 U.S.C. 331(j) and 360j(c)) from dis-

closing such information from PMA’s or files for investi-

gational devices under development pursuant to an investi-

gational device exemption (IDE) because such information

constitutes trade secret data. Lacking information about

polymer formulation and manufacturing processes, it is

not possible to compare one rigid gas permeable lens to

another for the purpose of determining substantial equiva-

lence; individual CAB and polyacrylate-silicone lenses are

snfficiently different from one another that the fact that

they are made from CAB or polyacrylate-silicone does not

allow an inference of comparable safety and effectiveness.

In summary, clinical evidence of the safety and effective-

ness of a limited number of individual lenses. characterized

only by general family of material, i.e. CAB or polvacryl-

a‘e-silicone, brand name, and manufacturer, would be in-

sufficient to serve as a basis for reclassification of a generic

type of device.

D. Inadequacy of Class { or Class [I to Provide Reasonable

Assurance of Safety and Effectiveness

Two comments from proponents of reclassification argue

in response to questions 1.b. and 5.b. above that the safety

and effectiveness of polyacrylate-silicone lenses, as identi-

fied in a definition offered by both comments, can be evalu-

ated against a group of parameters with assigned accept-

ance limits that are proposed in these comments as criteria

for the determination of substantial equivalence after the

reclassification of such lenses into class I. These parameters

include certain physical, optical, chemical, toxicological,

end biocompatib'lity criteria, but exclude clinical evalua-

tion. The comments argue that lenses that met the assigned

36a

limits for the parameters would be safe and effective,

which would negate the need for clinical trials as well as

the need for identification of the lenses with detailed in-

formation on polymer formulation and manufacturing

processes. The comments accordingly argue that the ab-

sence of information concerning formulation and process-

ing is not a bar to reclassification. The comments further

argue that use of these parameters would allow FDA to

determine substantial equivalence of new lenses to reclassi-

fied lenses and would ensure the adequacy of FDA review

of premarket notification submissions to screen out unsafe

or ineffective lenses. Other comments argue that to estab-

lish such parameters as criteria for determining substantial

equivalence to a class I device would be de facto imposition

of a performance standard. These comments urge the

agency to use such parameters as the basis for the develop-

ment of a performance standard under section 514 of the

act, and to reclassify the lenses into class IT.

To suffice as a basis for reclassification into class I or

class II, such a group of parameters, whether used to

determine substantial equivalence or as the basis for a

performance standard, would of necessity have to be shown

capable of providing reasonable assurance of safety and

effectiveness of the lenses bv valid scientific evidence. No

comments contained, and FDA is unaware of, any evidence

that if a lens met these parameters, there would be reason-

able assurance that the lens was safe and effective, or in

the event of reclassification, that the lens would be sub-

stantially equivalent in terms of safety and effectiveness

to any lens that had been reclassified. The absence of the

requisite evidence precludes using the parameters offered

by the comments as a basis for reclassification of rigid gas

permeable lenses into class I or class II.

E. Need for Clinical Trials

Several comments argue that the results of nonclinical

laboratory studies cannot be used to predict the clinical

37a

performance of a contact lens. Other comments argue that

the clinical performance of a contact lens can be readily

predicted from nonclinical laboratory studies.

None of the comments submitted any data to support

their arguments. FDA is unaware of any combination of

nonclinical laboratory studies capable of predicting the

clinical performance of any contact lens on the human eve.

Such studies serve well to screen out materials that should

not go on to clinical trials. For example, in vitro or animal

toxicity tests of a material or a material extract may

reveal an overt cytotoxic effect to an undifferentiated cell

line (the correlation of this effect to an ocular response

in humans has not been established) or gross systemic or

ocular toxicity. These tests are presumptive in nature and

serve at best to provide reasonable assurance that subjects

in a clinical trial would not be placed at undue risk from

exposure to a new or modified material used to make a

contact lens. However, nonclinical laboratory studies cannot

provide any data on human ocular biocompatibility, or on

adequacy of design (e.g., weight, thickness, geometry, cen-

tration). comfort, stability, durability, fit, and visual acuity,

nor can the results of such studies be used as the sole basis

from which to predict the clinical performance of an ap-

proved contact lens for which approval for a new indica-

tion is sought.

FDA believes that the safety and effectiveness of a

contact lens is a function of the complex interrelationship

of material. design, and manufacture that results in a

unique set of physical, chemical, mechanical, and optical

characteristics. When prescribed and fitted properly. a

lens with this unique set of characteristics should provide

safe and effective visual correction in a human eye with a

specific diagnosed ametropia. FDA believes that contact

lenses made from a new material, including material that

has been significantly modified, contact lenses made to

significantly modified designs, and contact lenses for which

38a

approval for a new indication is sought, cannot at this

time be shown to be safe and effective without clinical, as

well as preclinical, evaluation.

F. Conclusion

FDA has carefully reviewed and analyzed all the com-

ments received as well as the oral and written testimony

presented at the public hearing and has further reviewed

the data discussed in the preamble to the proposed rule.

On the basis of all this information, FDA has concluded,

contrary to the tentative conclusions stated in the proposal,

that there is insufficient valid scientific evidence to show

that the rigid gas permeable lenses proposed for reclassi-

fication are safe and effective, to characterize the device

adequately for the purpose of reclassification, or to demon-

strate that either class I or class IIT would provide reason-

able assurance of the safety and effectiveness of the device.

Class ITI is still necessary to provide reasonable assurance

of the safety and effectiveness of rigid gas permeable

lenses. .

This document withdraws FDA’s first proposal to re-

classify a device under section 513(e) of the act. The

agency initiated this proceeding because it tentatively con-

cluded that the new, publicly available, valid scientific evi-

dence of safety and effectiveness it had gathered was suffi-

cient to show that rigid gas permeable lenses shculd not

remain in class III and that class I would provide reason-

able assurance of the safety and effectiveness of the lenses.

However, as shown by the specific issues raised in the pre-

amble to the proposed rule (47 FR 53410), the April 15,

1983 notice reopening the record, and the agency’s decision

to hold a public hearing on the proceeding (see 48 FR

18836), FDA was concerned about the sufficiency of the

evidence it relied on in the proposal, and promulgation of

a final rule reclassifying the lenses was far from certain.

In response to the notice-and-comment procedures man-

39a

dated by the act and the regulations, as well as the public

hearing on the proposal, FDA received comments and oral

and written testimony that required it to reevaluate the

evidence upon which it relied in the proposal, and to evalu-

ate additional information presented by interested persons.

As a result of its evaluation and reevaluation of all the

_ information in the record of this proceeding, FDA learned

that the safety and effectiveness data summarized in the

preamble to the proposal were seriously deficient in many

respects, that lenses made of CAB or polyacrylate-silicone

are the products of complex polymer formulation and

manufacturing processes, that the information it would

have to require in a premarket notification submission to

determine whether a new lens is substantially equivalent

to a reclassified lens would exceed the authority of section

510(k) of the act and Subpart E of Part 807 of the regu-

Istions governing premarket notification procedures (?1

CFR Part 807, Subpart E), and that there is not sufficient

valid scientific evidence to develop a performance standard

under section 514 of the act to provide reasonable assur-

ance of the safety and effectiveness of rigid gas permeable

lenses. In short, FDA learned that at this stage in their

development, there is no substitute for clinical tria!s to

provide reasonable assurance of the safety and effective-

ness of these lenses.

If. ANALYSIS OF COMMENTS

The agency received appreximaieiy 200 comments on the

proposal, including written and oral testimony presented

at the May 26, 1983 public hearing. Comments were re-

ceived from manufacturers of contact lenses and contact

lens materials, optical latoratories, clinical investigators

of contact lenses, industry associations. members of Con-

gress, and other interested persons. The following is a

summary of the significan: comments received and FDA’s

responses to them.

40u

A. Classification

1. One comment suggests that rigid gas permeable lenses

are not class ITI devices under section 520(1)(1)(E) of the

act. According to the comment, the notice published in the

FEDERAL REGISTER of September 30, 1975 (40 FR

44844), which declared as new drugs contact lenses con-

sisting of polymers other than polymethylmethacrylate

(PMMA), was principally concerned with hydroxyethyl-

methacrylate (HEMA) contact lenses and was grounded

on incorrect information as to the composition of then

marketed PMMA lenses. The comment points out that then

marketed PMMA lenses did not consist ‘‘entirely’’ of

PMMA, citing the preamble to the proposed rule (47 FR

53404). The comment then argues that if the September

30, 1975 notice, which included a proposed rule to codify

the agency’s position, had not been withdrawn by a notice

published in the FEDERAL REGISTER of January 13,

1978 (43 FR 1966), literal application of the September 30,

1975 notice would have required FDA to regulate all con-

tact lenses as new drugs before enactment of the amend-

ments. The comment also argues that the September 30,

1975 notice, as allegedly interpreted by a notice published

in the FEDERAL REGISTER of December 16, 1977 (42

FR 63472) (the transitional notice) and the January 13,

1978 notice, applies only to HEMA (soft) lenses, and that

rigid gas permeable lenses are more closely related to

PMMA lenses than to soft lenses.

FDA disagrees with the comment. The term ‘‘soft’’ as

used in reference to contact lenses in the September 30,

1975 notice, the transitional notice, and the January 13,

1978 notice encompasses ail lenses other than those made

of PMMA. That one or more of these notices used the term

‘‘soft contact lenses’’ as a synonym for ‘‘non-PMMA

lenses’’ thus has no bearing on the classification of lenses

consisting of polymers other than PMMA. Furthermore,

the September 30, 1975 notice, which made it plain that

sd 8 eet dh

4la

FDA had in the past regarded, and would continue to

regard, as new drugs, contact lenses consisting of polymers

other than PMMA, expressly cited CAB, polycarbonate,

and silicone as examples of such other polymers (40 FR

44845). The notice, which advised that the agency had

taken this position since the 1960’s, accordingly applies to

rigid gas permeable as well as soft lenses.

As a result of the September 30, 1975 declaration, under

section 520(1)(1)(E) and (1)(3)(D)(i) of the act, non-

PMMA contact lenses on the date of enactment of the

amendments (the enactment date) were automatically

classified into class III without need for regulations or

other action on the part of the agency. The transitional

notice and the January 13, 1978 notice, which withdrew the

1975 proposed rule but did not affect its declaration, simply

provided interested persons further notice that non-PMMA

lenses were class III devices subject to the premarket ap-

proval requirements of section 515 of the act (21 U.S.C.

360e).

Although the September 30, 1975 notice stated that FDA

had in the past regarded, and would continue to regard,

contact lenses consisting ‘‘entirely of PMMA’”’ as dvvices,

the notice stated: ‘‘[t]he Agency has undertaken a study

to determine the extent to which adjuvants such as cross-

linking agents, resin bases, catalysts, colorants. and anti-

oxidants are used in the manufacture of contact lenses

consisting of PMMA to determine the effects of such ad-

juvants on the essential physicochemical characteristics of

PMMA and thus to determine which of these contact lenses

may be regarded as devices and which should be regarded

as new drugs’’ (40 FR 44845). The September 30, 1975

notice thus recognized that then marketed PMMA lenses

did not consist ‘‘entirely’’ of PMMA, and ‘“‘literal appli-

cation’’ of the notice would not have required FDA to

regulate all contact lenses as new drugs before enactment

of the amendments.

42a

FDA acknowledges that rigid gas permeable lenses are

more closely related te PMMA lenses than to soft lenses.

However, the components of rigid gas permeable lenses,

e.g., CAB, silicone acrylate monomers, and derivatives of

acrylate monomers, are not adjuvants. For this reason, as

well as by the express terms of the September 30, 1975

notice, rigid gas permeable lenses are not PMMA lenses

within the meaning of that notice.

FDA advises that any CAB lens for which a new drug

application (NDA) was filed and no order of approval or

refusal to approve had been issued on the enactment date,

e.g., MESO Contact Lens, is a class III device under sec-

tion 520(1)(1)(B) of the act; that any CAB lens for which

a notice of claimed investigational exemption for a new

drug (IND) was in effect on the enactment date, e.g.,

MESO Contact Lens, CABCURVE® Contact Lens, is a

class III device under section 520(1)(1)(C) of the act;

and that any CAB lens that is substantially equivalent to

a CAB lens covered by section 520(1)(1)(B) or (C) is a

class III device under section 520(1)(1)(D) of the act.

FDA advises that any polyacrylate-silicone lens for

which an IND was in effect on the enactment date, e.g.,

POLYCON®, is a class III device under section 520(1)

(1)(C) of the act and that any polyacrylate-silicone lens

that is substantially equivalent to a polyacrylate-silicone

lens covered by section 520(1)(1)(C) of the act is a class

IIT device under section 520(1)(1)(D) of the act.

B. Identification

2. One comment argues that CAB and polyacrylate-

silicone lenses constitute a generic type of device having

essentially the same characteristics and that, under 4 860.-

120(b) of the regulations governing reclassification, any

reclassification should extend to all devices fallimg within

that generic type. The comment recommends that proposed

) 886.5360 (21 CFR 886.5360) be amended to provide a

43a

generic description of the device by eliminating the limita-

tion to lenses in commercial distribution. Another comment

argues that the proposed rule, which the comment charac-

terizes as based on the composition of the device and its

status as a contact lens subject to approved NDA’s or

PMA’s, is unsound as a matter of policy and violates sec-

tion 520(c) of the act. The comment points out that FDA,

in the preamble to the proposed rule to classify ophthalmic

devices, stated: ‘‘[i]t is not practical for FDA to publish

an identification of each type of device that is so detailed

as to anticipate every product feature that may be relevant

in determining whether a new device is substantially equiv-

alent to previous devices classified by regulation. * * * ’’

(47 FR 3695; January 26, 1982). The comment claims that

classification must reflect the potential risk of illness or

injury and the need for varying levels of controls associ-

ated with the type or category of device rather than the

specific device, and states that this focus on the type or

category of device and the risks associated with such type

or category has been FDA’s previous approach to classifi-

cation of all ophthalmic devices under the act and is re-

quired by the act. For these reasons, the comment requests

that FDA withdraw proposed § 886.5360 and, if reclassifi-

cation is deemed warranted, propose a classification of the

category or type of device identified as ‘‘contact lenses.’’

FDA agrees that the identification paragraph of any

classification regulation should provide a generic descrip-

tion of the device. As explained in sections II.B. and C.

and paragraphs 13, 23, and 24 of this document, however,

the lens proposed for reclassification—a daily wear spheri-

cal lens consisting of CAB or polyacrylate silicone—has

not been adequately characterized for the purpose of re-

classification. Accordingly, identification of the generic type

of device as ‘‘the contact lens,’’ or even ‘‘the rigid gas

permeable lens,’’ even broader identifications than included

in the proposal, could not be adequate for that purpose.

FDA notes that if the proposed rule had been revised and

44a

promulgated to identify the generic type of device as ‘‘the

rigid gas permeable lens,’’ or as ‘‘the contact lens,’’ and a

manufacturer had submitted a premarket notification seek-

ing to market a new lens, FDA, to determine whether the

new lens was substantially equivalent to any lens in the

generic type, still would have compared the new lens to

lenses already covered by the final rule (see § 807.87(f) and

(h) of the regulations governing premarket notification

procedures).

FDA disagrees that identifying a device based on its

composition or regulatory status violates the letter or the

spirit of the act or the regulations issued under it. So long

as there is sufficient valid scientific evidence showing (1)

why a device should not remain in its present classification

and (2) that a change in its classification will provide rea-

sonable assurance of the safety and effectiveness of the

device, nothing in section 520(c) of the act or any other

section of the act, or in any of the regulations implement-

ing any section of the act, precludes identifying the device

by composition and previous status under section 505 (21

U.S.C. 355) or 515 of the act. FDA notes that the proposed

rule to classify ophthalmic devices includes a proposal to

classify into class II a device, namely, the PMMA contact

lens, identified in part by composition (47 FR 3736).

C. Adequacy and Safety and Effectiveness Data

3. Several comments state that rigid gas permeable

lenses may not be reclassified into a class other than class

III unless there is adequate valid scientific evidence of

safety and effectiveness to support reclassification.

FDA agrees with these comments (see the preamble to

the proposed rule (47 FR 53404) and section I.A. of this

document). Lacking adequate valid scientific evidence that

rigid gas permeable lenses are safe and effective, and that

class I would be sufficient to provide reasonable assurance

of the safety and effectiveness of such lenses, FDA may

not reclassify them from class ITI into class I or class II.

«

45a

4. One comment states that the burden of proof that

reclassification is appropriate is on FDA and on those who

support reclassification, regardless of whether those oppos-

ing reclassification can or do submit evidence showing that

reclassification is not appropriate.

FDA agrees with this comment. The legal standard for

reclassification is set out in the preamble to the proposed

rule (47 FR 53404) and in section IT.A. of this document.

FDA addressed the question of burden of proof in the

April 15, 1983 notice reopening the comment period (48

FR 16293) :

FDA recognizes that to reclassify the contact lenses

at issue in this rulemaking from class III into class I,

it must have new, publicly available, valid scientific

evidence of safety and effectiveness demonstrating why

the lenses should not remain in class III and why the

‘*general controls’’ authorized by the act will provide

reasonable assurance of the safety and effectiveness

of the lenses. * * * Although this notice requests spe-

cific evidence showing why the lenses should not be

reclassified, as well as evidence showing why they

should be reclassified, FDA has not shifted the burden

of proof to those opposing reclassification.

5. Several comments argue that the evidence needed to

reclassify a contact lens is at least equal to that which

would be necessary to meet FDA’s guideline concerning

testing of contact lenses, ‘‘FDA Contact Lens Guidelines

on Toxicology, Microbiology, Clinical Manufacturing Evalu-

ation and Controls’’ (Ref. 5 of the proposal) (the contact

lens guideline), and that FDA may not reclassify a lens

proposed for reclassification unless the valid scientific

evidence of the safety and effectiveness of that lens meets

the criteria of the guideline.

FDA guidelines state procedures or standards of general

applicability that are not legal requirements but are accept-

46a

able to FDA for a subject matter which falls within the

laws administered by the Commissioner (21 CFR 10.90(b)).

Conformance to the contact lens guideline accordingly is

not a legal prerequisite for premarket approval. It follows

that conformance to the guideline is not a lega! prerequisite

for reclassification of contact lenses. The evidence of safety

and effectiveness of the contact lenses proposed for reclassi-

fication has been evaluated by FDA against the criteria

for valid scientific evidence specified in § 860.7 of the regu-

lations.

FDA believes that the evidence needed to show that a

rigid gas permeable lens is safe and effective for the pur-

pose of reclassification is similar, but not necessarily iden-

tical to, the evidence suggested in the contact lens guide-

line to show safety and effectiveness for premarket ap-

proval. For example, for the purpose of reclassification,

comprehensive clinical data combined with detailed infor-

mation on polymer formulation and manufacturing pro-

cesses might obviate the need for the detailed reporting of

preclinical testing suggested in the guideline.

6. Several comments refer to FDA’s statement in the

preamble to the proposed rule that the safety of rigid gas

permeable lenses is shown by the absence of reports in the

literature of serious, irreversible adverse effects on health

presented by the device, and the absence of such reports

in FDA’s Device Experience Network (DEN). The com-

ments argue that rather than serving as evidence for re-

classification of the device, the lack of evidence of such

adverse effects is evidence of the success of the present

class III classification in assuring that only safe and effec-

tive lenses are marketed. The comments further argue that

extrapolation from the safety record of approved devices

to that of future deregulated devices is inappropriate.

The comments do not accurately restate the preamble,

which cited the absence of reports in the literature as one

item of evidence of the safety of rigid gas permeable lenses

47a

and simply noted that no serious, irreversible adverse

effects on health presented by the device had been reported

to DEN (47 FR 53405). FDA agrees, however, that the

safety record of rigid gas permeable lenses to date repre-

sents the performance of lenses for which there are ap-

proved PMA’s. The agency acknowledges that DEN is not

comprehensive and advises that the mere absence of nega-

tive reports in this voluntary reporting system cannot

establish the safety of a device. Before a device may be

reclassified under section 513(e) of the act from class IIT

into class I or class II, the act and the regulations require

that the safety, as well as the effectiveness, of the device

be established by valid scientific evidence.

7. A few comments suggest that FDA has not conducted

an adequate search for evidence of serious or permanent

injury from contact lens wear. One comment provided

copies of published articles dealing with complications

caused by certain silicone elastomer lenses marketed in

Germany and Japan; other comments provided bibliogra-

phies of published articles dealing with injuries allegedly

related to contact lens wear.

Before issuing the proposed rule, FDA searched dili-

gently for evidence of serious, irreversible adverse effects

presented by each of the lenses proposed for reclassification

when used in accordance with its labeling and under proper

professional supervision, and found no such evidence.

Since then, FDA has reviewed articles cited in the com-

ments as containing evidence of such effects. This latest

review confirms FDA’s earlier findings. Injuries to the eve

related to use of approved contact lenses invariably are

traceable to factors associated with improper lens use,

care, or fitting. While such reports of injuries argue force-

fully for the need for continued diligence in the regulation

of contact lenses, they do not preclude reclassification if

there is adequate, valid scientific evidence of the safety and

effectiveness of the devices when used and fitted properly.

48a

The silicone elastomer lenses associated with the re-

ported complications in wearers of the lens in Germany

and Japan were not, as admitted in the comment, of the

type proposed for reclassification, and by definition would

require premarket approval before being marketed in the

United States.

8. One comment argues that safety and effectiveness data

for contact lenses having different clinically significant

properties and design characteristics cannot be pooled to

show the safety and effectiveness of all lenses consisting of

CAB or all lenses consisting of polyacrylate-silicone. The

comment states that there are thousands of formulations

of CAB which vary from one another in such significant

characteristics as toxicity and dimensional stability. The

comment concludes that generally accepted scientific meth-

ods for use of test results would dictate that data for

lenses with differing safety and effectiveness parameters

not be pooled.

FDA agrees with this comment. Data on the polymer

formulation and manufacturing processes for the different

approved CAB lenses are not publicly available. Unless

the CAB lenses are shown to be identical by such data, the

agency may only assume that each CAB lens has different

safety and effectiveness parameters from other such lenses.

In addition, pooling of the clinical safety and effectiveness

data on which the proposed rule was based would be in-

appropriate because of the deficiencies in the data (see

paragraphs 10 through 12 of this document). There is in

the record no information identifying by polymer formula-

tion, manufacturing process, and related parameters any

of the rigid gas permeable lenses proposed for reclassifica-

tion. Absent such information, the safety and effectiveness

of one rigid gas permeable lens cannot be compared with

the safety and effectiveness of another rigid gas permeable

lens. This lack of characterizing data precludes pooling

of data from clinical investigations.

49a

9. In response to question 3 in the preamble to the pro-

posed rule, two comments argue that any reclassification

of rigid gas permeable lenses should include indications

for the correction of hyperopia and aphakia as well as

myopia because there appears to be no basis upon which

to limit to specifie refractive corrections the significance

of the data presented in the preamble. Five comments argue

on the contrary that data showing that a lens is safe and

effective for myopia cannot be used to support the safety

and effectiveness of the lens for the correction of byperopia

and aphakia. These comments state that lenses indicated

for the correction of hyperopia and aphakia are of neces-

sity significantly different in design and geometry from

lenses indicated for the correction of myopia. These com-

ments also state that lenses for the correction of hyperopia

and aphakia generally require an increased lens center

thickness compared to lenses for the correction of myopia.

Increased lens center thickness results in a reduction in

the oxygen permeability of the lens and concomitant safety

and effectiveness concerns unique to these lenses, accord-

ing to the comments. Therefore, the comments opposing

reclassification conclude that only clinical trials can pro-

vide reasonable assurance of safety and effectiveness of a

contact lens indicated for the correction of hyperopia or

aphakia.

Because FDA is withdrawing the proposed rule, the

question whether FDA may reclassify rigid gas permeable

lenses for myopia, hyperopia, and aphakia based solely or

primarily on data showing that the device is safe and

effective for the correction of myopia, or myopia and

aphakia, is moot. FDA advises, however, that none of the

comments provide any evidence to support the contention

that reclassification of rigid gas permeable lenses indicated

for the ecrrection of myopia, hyperopia, and aphakia could

be based solely or primarily on data demonstrating that

the lenses are safe «.." effective for the correction of my-

opia or for the con «‘ion of myopia and aphakia.

50a

FDA agrees with the comments that argue that the lens

characteristics required to provide safe and effective cor-

rection of hyperopia or aphakia are significantly different

from the lens characteristics required to provide safe and

effective correction of myopia. However, lenses indicated

for the correction of hyperopia and aphakia may be identi-

cal in design and concomitant safety and effectiveness

characteristics where the range of magnification for the

two indications overlap. The aphakic eye is a worst case

for both safety and effectiveness considerations for a con-

tact lens because of physiological changes to the cornea

from the insult of surgery. Among other things, these

changes could result in alterations in corneal oxygen re-

quirements. Consequently, FDA advises that for lenses

identical in material, design, and magnification range, the

safety and effectiveness of a lens for the correction of

hyperopia may, in large measure, be inferred from evi-

dence of the safety and effectiveness of a lens for the

correction of aphakia. Similarly, if the safety and effec-

tiveness concerns that are unique to a lens intended for

the aphakic eye are adequately addressed by clinical trials

of the lens in aphakic eyes, the safety and effectiveness of

that lens may, in large measure, be inferred from evidence

of its safety and effectiveness for the correction of hyper-

opia. FDA advises, however, that it has not been demon-

strated by valid scientific evidence that the safety and

effectiveness of a lens for the correction of hyperopia can

be inferred solely from evidence of the safety and effective-

ness of a lens for the correction of aphakia, or that the

safety and effectiveness of a lens for the correction of

aphakia can be inferred solely from evidence of the safety

and effectiveness of a lens for the correction of hyperopia.

10. One comment generally criticizes the published arti-

cles (Refs. 22-27 (see 47 FR 53411)) relied on in the pre-

amble to the proposed rule as valid scientific evidence of

the safety and effectiveness of CAB lenses. The comment

states that the articles are deficient in that they do not

ee

Sla

consistently state clear objectives, that they do not have

an adequate method of subject selection, that they do not

include sufficient information to allow comparisons between

test and control groups, and that most of the articles are

based on retrospective clinical evaluation, and therefore

suffer from the bias of evaluating successful patients. The

ocular data, and implies that the number of patients studied

is inadequate.

FDA acknowledges that .the articles criticized by the

comment have some deficiencies in study protocols, in pa-

tient selection criteria, in the number of patients studied,

or in reporting of important clinical results. FDA notes

that no evidence of the safety or effectiveness of any CAB

lens was included in or submitted with any comment on

the proposed rule. Consequently, the deficiencies noted in

the comment and which, as discussed below, show that the

articles do not constitute valid scientific evidence of safety

and effectiveness, preclude reclassification of CAB lenses.

a. “‘A Clinical Study of CAB Lens Wear’’ by Kline and

DeLuca (Ref. 22). This study, which apparently was retro-

spective, reports on 100 myopic patients who could tolerate

an unidentified CAB lens on an initial visit. The investi-

study lens is safe and effective for daily wear.

b. “‘Clinical Experience with the Cabcurve Contact

Lens’’ by Sigband (Ref. 23). This study reports on 65 pa-

tients, including 54 myopes, 4 hyperopes, and 7 aphakes,

who were ‘‘contact lens failures.’ The study includes no

data on visnal acuity, except a table of summarizing best

52a

visual acuity achieved, and no data on any other evaluation

criterion. The study population, which included only 55

successful patients, is small. However, the question of size

is overshadowed by the absence of adequately reported

data on any significant evaluation criterion.

c. ‘‘Gas-Permeable Cellulose Acetate Butyrate (CAB)

Contact Lens’? by Hales (Ref. 24). This study, which ap-

parently is retrospective, reports on 50 patients who had

been unsuccessful wearers of hard contact lenses and who

were subsequently fitted with an unidentified CAB lens.

The study contains one chart of visual acuity with CAB

lenses as compared to visual acuity with hard lenses. No

other data are provided. The small retrospectively reviewed

patient population and the absence of data for any criterion

except visual acuity renders this study inadequate to deter-

mine the safety and effectiveness of the lens under study.

d. “‘Oxygen-Transmitting Hard Contact Lens’’ by Man-

dell (Ref. 25). This study alludes to an experiment in which

nine PMMA contact lens wearers were refitted with an un-

identified CAB lens to determine whether the change would

alleviate persistent edema associated with wearing the

PMMA lenses. No data are provided on any criterion ex-

cept edema. The study does not purport to establish the

safety and effectiveness of lenses made of CAB.

e. ‘Extended Wear of CAB Contact Lenses in Aphakic

Patients’’ by Garcia (Ref. 26). This study appears to be

a well-conducted study of continuous extended wear (for

1 to 6 weeks between removals for cleaning) of a CAB

lens for the treatment of aphakia. Patients were followed

for an average of 24 months. However, the study’s sum-

mary presentation of data does not allow scientific evalua-

tion of the safety and effectiveness of the lens for continu-

ous wear, or therefore, for daily wear. For example, the

report contains no visual acuity data or quantitative data

on edema, slit lamp findings, or epithelial staining, which

are all necessary to permit scientific evaluation of the

53a

safety and effectiveness of the lens. Because the study

“‘lack[s] sufficient details to permit scientific evalnation,’’

the study is ‘‘not regarded as valid scientific evidence to —

show safety or effectiveness’’ (21 CFR 860.7(c)(2)). The

study lenses were identified as the Rynco Scientific Corp.

Rx 56 Lens (used early in the study) and the Danker and

Wohik, Inc., Meso CAB lens (used late in the study).

f. ‘Corneal Response to Extended Wear of CAB Con-

tact Lenses in Aphakia’’ by Kaplan and Triber (Ref. 27).

The purpose of this study was to determine the effect of

extended wear of Danker Labs., Inc. MESO CAB lenses

on corneal thickness. The authors make no claim of estab-

lishing the safety or effectiveness of CAB lenses.

In conclusion, FDA agrees with the comment that Refs.

22-27 are inadequate to show the safety and effectiveness

of CAB lenses.

11. A few comments state that the two published articles

relied on in the preamble to the proposed rule (‘Clinical

Evaluation of the Polycon 8.5 Design’’ (Ref. 30) and ‘‘Pa-

tient Responses to Gas-Permeable Hard ( Polycon) Contact

Lenses’’ (Ref. 31); see 47 FR 53411) do not constitute

adequate valid scientific evidence of the safety and effec-

tiveness of the specific polyacrylate-silicone lens reported

on. Therefore, the comments argue that the articles cannot

constitute adequate valid scientific evidence of the safety

and effectiveness of all contact lenses made of polyacrylate-

silicone and proposed for reclassification. The comments

state that Ref. 30 defines success as the ability io wear the

lens for 10 hours per day, but includes no data from which

to determine either safety or effectiveness, i.e., there are

no data on epithelial staining, neovascularization, corneal

edema, change in keratometry readings, corneal thickness,

endothelial cell counts, or visual acuity before or after lens

wear. Further, the comments state that although Ref. 31

includes most of the data believed to be necessary to evalu-

ate a lens, it reports on only 46 patients and does not

indicate how long the patients in the study were followed.

d4a

FDA agrees with these comments. All the data referred

to by the comments are essential to any determination of

the safety and effectiveness of a contact lens. Ref. 30 con-

tains insufficient data to allow a scientific judgment of the

safety and effectiveness of the lens under study. Ref. 31,

with only 31 successful study patients and an indefinite

followup period, is insufficient to demonstrate the safety

and effectiveness of the lens under study because the study

population is too small to generalize in a meaningful way

and because no quantitative data are provided for any

significant evaluation criterion except edema. It necessarily

follows that because the data included in Refs. 30 and 31

do not provide sufficient valid scientific evidence of the

safety and effectiveness of the lenses studied by the in-

vestigators, Refs. 30 and 31 cannot establish the safety

and effectiveness of lenses not included in the studies.

12. A few comments, including a comment from the lens’

manufacturer, discuss Refs. 30 and 31 of the proposal and

state that the material used to make the lenses in these

studies, identified only as POLYCON®, has been repiaced

by an improved material, POLYCON II® and tinted

POLYCON II®. The comment from the manufacturer

points out that the two latter lenses were approved by

FDA only after preclinical and clinical studies following

FDA’s contact lens guideline demonstrated that lenses

made of the new materials were safe and effective. The

comment from the manufacturer further states that POLY-

CON® and POLYCON II® materials differ in polymer

constituent ratios with concomitant differences in oxygen

permeability and wettability, major factors in determining

safety and effectiveness. The comments argue that FDA

never would have approved the PMA for the POLYCON®

lens, much less the POLYCON II® lens, on the basis of the

data in the cited references. Consequently, the data cannot

be an adequate basis for reclassification of the general

category of polyacrylate-silicone lenses.

55a

FDA agrees with these comments. FDA required com-

plete nonclinical laboratory studies and clinical investiga-

tions for the POLYCON IT® and tinted POLYCON II®

lenses because changes had been made in the polymer ratios

in the first case, and in certain polymer constituents in the

second case. The evidence of safety and effectiveness of

lenses of POLYCON® was therefore determined to be

inapplicabi: to POLYCON IT® and to tinted POLYCON

IT®. The data in the cited studies would not have been

adequate to support premarket approval of POLYCON®

and would have been considered inapplicable to POLYCON

IT®. It follows that the data in the cited studies are insuffi-

cient to show the safety and effectiveness of polyacrylate-

silicone lenses as a generic type of device for the purpose

of reclassification.

13. Six comments submitted data from clinical investiga-

tions of two different polyacrylate-silicone contact lenses,

the Paraperm 02™ and the Optacry] 60, covering a total of

approximately 1,100 patients. One of the comments also

included data from the laboratory testing (preclinical

evaluation) of the Optacryl 60 lens. The comments argue

that these data, most of which were the same as the clinical

and preclinical data submitted in PMA’s for these lenses,

constitute ample valid scientific evidence of safety and

effectiveness to serve as the basis for reclassification of

rigid gas permeable lenses made of polyacrylate-silicone.

The comments further argue that similarity of favorable

resuits between the different varieties of polyacrylate-

silicone show that the polyacrylate-silicone lenses consti-

tute a generic type of device and that changes in polymer

ratios do not give rise to divergent clinical results.

FDA disagrees with these comments. Questions concern-

ing the completeness of the submitted data are discussed

in paragraph 14 of this document. Those questions aside,

none of the comments contains polymer formulation or

manufacturing processes or any other information that

56a

would allow characterization of the lenses studied, and as

explained in sections II.B. and C. and paragraphs 23 and

24 of this document, evidence of the safety and effective-

ness of a specific polyacrylate-silicone lens cannot be gener-

alized to another polyacrylate-silicone lens without such

information.

Taken at face value the data submitted with these com-

ments support the conclusion that the lenses designated as

the Paraperm 0:™ and Optacryl 60 are safe and effective.

However, because the polymer ratios of the two lenses were

not identified in the comments, conclusions pertaining to

the effect on safety and effectiveness of differences in poly-

mer ratios cannot be drawn. The assumption that the poly-

mer ratios of Paraperm 0:™ and Optacryl 60 are different

only allows the conclusion that polyacrylate-silicone lenses

of more than one polymer ratio may be found to be safe

and effective. It does not logically follow that changes in

polymer ratios do not give rise to divergent clinical results.

Changes in the ratio of the principal ingredients of

polyacrylate-silicone polymers, as illustrated by the follow-

ing table, adapted from a table in a U-S. Patent for a poly-

acrylate-silicone lens material (Ref. 1), can be expected to

result in significant changes in the oxygen permeability of

lenses made from the ingredients listed in the table. Differ-

ences in oxygen permeability of the magnitude shown on

the chart can be expected to give rise to divergent clinical

results that significantly affect safety and effectiveness

(Refs. 1 and 2).

57a

Composition

SIGMA EGMA EDMA MMA Oxygen permeability (Dk)

parts mL.cm./om.*sec.cm.Hg

30 5 5 60 30X10"

40 7 5 48 62X10

50 9 5 36 114X110"

60 ll 5 24 184 xX id

70 13 5 12 25.5 X 10°

80 10 5 5 318 xX 10°

NOTE: ,

EGMA: Ethylene glycol monomethacrylate

EDMA: Ethylene glycol dimethacrylate

MMA: Methyl methacrylate

SIGMA is identified in the text of the patent as:

Methyldi-(trimethylsiloxy) sylylpropylglycerol methacrylate.

Oxygen permeability (Dk) is expressed as the product of the

diffusion coefficient for O02 movement in the material (D) and the

solubility constant for O; in the material (k).

14. Two comments question whether the safety and effec-

tiveness data submitted with other comments on the Para-

perm O:™ and Optacryl 60 contact lenses constitute valid

scientific evidence of the safety and effectiveness of these

lenses. The comments point out that the data submitted

cover approximately 1,100 subjects whereas the studies in-

cluded more than 100,000 subjects. The comments question

the basis for selection of the subjects included in the sub-

mitted data, whether the selection process biased the re-

58a

sults of the studies, what the incidence was of adverse

reaction in the total study population, and what efforts

FDA has made to establish that these data do not repre-

sent a select subject population or group. The comments

argue that if these questions are open, the data cannot be

considered to be valid scientific evidence of safety and

effectiveness.

In general, absent information about effectiveness and

the incidence of adverse reactions in a total study popula-

tion, and how the data submitted were selected from those

available, FDA cannot determine whether the submitted

data show, by valid scientific evidence, that an investiga-

tional device is safe and effective (see, e.g., § 860.7(f) (1)

(ii) and (v)). In any event, because the lenses in the clini-

cal investigations are only identified by general family of

material, i.e., polyacrylate-silicone, brand name, and manu-

facturer, and no information is provided to characterize

them by polymer formulation or manufacturing processes,

the data do not and cannot show the safety and effective-

ness of polyacrylate-silicone lenses as a generic type of

device for the purpose of reclassification (see sections II.B.

and C. and paragraphs 13, 23, and 24 of this document).

15. Two comments state that the cata from the clinical

investigations of the Paraperm 0:™ and the data from

nonclinical laboratory studies and clinical investigations

of the Optacryl 60 polyacrylate-silicone rigid gas perme-

able lenses, discussed in paragraphs 13 and 14 of this docu-

ment, have been reviewed by the Ophthalmic Device Sec-

tion of the Ophthaimic; Ear, Nose, and Throat; and Dental

Devices Panel (the Section), an FDA advisory committee,

during the Section’s review of PMA’s for the subject

lenses. The comments argue that because the Section rec-

ommended approval of the PMA’s for the Paraperm 02™

lens and the Optacryl 60 lens, the data constitute valid

scientific evidence within the meaning of § 860.7(c).

59a

The question whether the data constitute valid scientific

evidence of the safety and effectiveness of the studied

lenses is discussed in paragraph 14 of this document. FDA

advises that during the Section’s review of the PMA’s,

the Section did not consider all the issues relevant to re-

classification, e.g., the adequacy of the characterization of

the devices or the adequacy of class I or class II to provide

reasonable assurance of the safety and effectiveness of the

devices. In any event, a PMA approval recommendation

from an advisory committee simply is a recommendation

and is not a determination by FDA that data in the PMA

constitute valid scientific evidence.

16. More than 100 comments were received from pro-

fessionals in the contact lens industry who regularly pre-

scribe, fill prescriptions for, and fit contact lenses. More

than 80 of these comments were from persons who identi-

fied themselves as investigators of polyacrylate-silicone

contact lenses. As defined in § 812.3(i) of the regulations

providing procedures for the conduct of clinical investi-

gations of devices (the IDE regulations) (21 CFR 812.3

(i)), an investigator is an individual who gathers safety

and effectiveness data for a sponsor who intends’ to seek

premarket approval for a device. Each of the more than

100 comments favors reclassification of polyacrylate-sili-

cone lenses from class IIT into class I.

FDA responds to these comments in paragraphs 17 to

21 of this document.

17. The comments from investigators argue that the

data gathered as a result of the investigators’ studies and

similar investigations provide more than ample valid scien-

tifie evidence of the safety and effectiveness of polyacryl-

ate-silicone contact lenses. Some investigators, including

one investigator who studied 1,100 polyacrylate-silicone

lenses, one who studied 3,000 polyacrylate-silicone lenses,

and one who studied 7,000 polyacrylate-silicone lenses, cite

the number of lenses studied.

60a

FDA disagrees with these comments, the number of

lenses investigated notwithstanding. FDA is prohibited by

section 520(c) of the act from using as the basis for the

reclassification of a device trade secret or confidential

commercial information obtained under section 520(g) of

the act (exemption for devices for investigational use).

Consequently, except for those trade secret and confidential

commercial data from clinical investigations that were made

public in other comments and that are discussed elsewhere

in this document, such data gathered by investigators are

not available to FDA for the purpose of reclassification.

18. As evidence of safety, more than 30 investigators

state that in their use of polyacrylate-silicone contact

lenses, they have observed no adverse reactions.

Statements by individual investigators that no adverse

reactions were found do not constitute valid scientific evi-

dence within the meaning of § 860.7 of the regulations.

Section 860.7(c)(2) states in part ‘‘* * * reports lacking

sufficient details to permit scientific evaluation * * * are

not regarded as valid scientific evidence to show safety or

effectiveness.’’ To meet the test of valid scientific evidence

and permit scientific evaluation such reports need to in-

clude, at a minimum, a uniform scientifically acceptable

definition of adverse reaction, the number of patients

studied, and comprehensive summaries of the results of

examinations for edema and staining as well as slit lamp

examinations, and of all reports of discomfort, blurred

vision, and of patients who discontinued use of the lenses

or were otherwise lost to followup.

19. Several comments from investigators argue that

when all other things are equal, the polyacrylate-silicone

lenses that have been subjected to clinical investigations

are superior to PMMA lenses because the former have

been shown to be gas permeable and, thus, provide better

oxygenization of the cornea. These comments state that

this increase in oxygenization results in reduced edema

6la

and greater wearer comfort, and allows the lens to be

tolerated by the wearer for a longer period of time than

PMMA lenses. There are no significant differences in the

machining (lathing, grinding, and polishing) characteris-

tices of the two materials, according to the comments.

Therefore, the comments argue that any lens that can be

made of PMMA also can be made of polyacrylate-silicone.

Consequently, polyacrylate-silicone lenses should not be

classified into a higher class than lenses made of PMMA,

which FDA has proposed to classify into class IT.

FDA disagrees with these comments. The classification

of contact lenses made of PMMA is not legally relevant

to the classification of rigid gas permeable lenses. As dis-

cussed in the September 30, 1975 notice (40 FR 44845),

contact lenses made of PMMA have been marketed in the

United States since the early 1950’s. Due to their extensive

history of safe and effective human use, PMMA lenses

were regulated as devices prior to the enactment of the

amendments and thus never required administrative ap-

proval for marketing. In contrast, rigid gas permeable

lenses were first marketed in the United States in the

late 1970’s and always have required premarket approval.

Indeed, since the introduction of hydrophilic (soft) contact

lenses in the 1960’s, FDA has regarded all contact lenses

other than those made of PMMA as new drugs requiring

premarketing clearance (see paragraph 1 of this document).

The September 30, 1975 notice explains that the agency’s

decision to require such clearance for all contact lenses

made from non-PMMA materials ‘‘ * * * was based on a

recognition that new plastic materials that had not been

shown to be safe and effective [for use] were being intro-

duced for use in the manufacture of contact lenses. The

introduction of these new materials led to new lens design

and use, new manufacturing methods, and new methods

for lens care. [FDA] is concerned that the use of these

contact lenses may result in serious eye damage if the

new material of which they are composed is unsafe for

62a

use in the eye, if the user cannot feusibly care for the

lenses, or if the highly complex procedures for the manu-

facture of these lenses are not carefully controlled to assure

a product of uniform quality’’ (40 FR 44845).

As explained in paragraph 1 of this document, rigid gas

permeable lenses were automatically classified into class

ITI on the enactment date of the amendments in accord-

ance with section 520(1)(1)(B), (C), and (E) of the act.

Such lenses may only be reclassified into class I or class II

in accordance with the provisions of the act and the regu-

lations as discussed in the preamble to the proposed rvle

(47 FR 53404) and in section IT.A. of this dormment.

Neither the safety nor the effectiveness of pol,acrylate-

silicone lenses has been established by valid scientific evi-

dence other than in PMA’s. Furthermore, FDA is not

aware of, and no comments provided, evidence that there

are no significant differences in the machining characteris-

tics of PMMA and any of the formulations of polyacrylate-

silicone used to manufacture any of the investigational

lenses about which comments were submitted. On the con-

trary, one comment from an investigator cites machining

differences, including increased tool wear, longer polishing

times, and reduced yield for polyacrylate-silicone compared

to PMMA. FDA believes that these differences reflect po-

tential significant differences in the characteristics of

PMMA and polyacrylate-silicone lenses, for example, sur-

face finish and uniformity.

20. Ten comments from investigators note that approved

lenses are routinely modified in optical laboratories to

improve the fit for specific patients. The potential superior

fit of custom fitted lenses is cited as an advantage of the

investigational lenses over approved lenses, and as an

argument for reclassification. Custom fitted lenses, specifi-

eally the polyacrylate-silicone lenses under investigation

by those submitting comments, result, according to the

comments, in a better fit and concomitant better comfort

_ ie ot a

and tolerance for those patients whose eyes do not pre-

cisely match the dimensions of approved lenses. Approved

polyacrylate-silicone lenses are only available in a limited

number of configurations, according to the comments.

Therefore, the comments argue that custom fitted investi-

gational polyacrylate-slicone lenses allow successful fitting

of a larger portion of the potential lens wearing population

than is currently possible with approved polyacrylate-

silicone lenses. Custom fitted lenses also are said to allow

a more perfect fit for those patients for whom the best fit

of an approved lens is a compromise.

FDA acknowledges that some portion of the user popu-

lation cannot always be fitted successfully from a fixed set

of lenses, and that some of these individuals might be fitted

successfully through modification of off-the-shelf lenses.

FDA notes that nothing in the act or the regulations for-

bids optical laboratories from modifying approved lenses

to meet the needs of specific patients so long as the specifi-

cations of the lenses, as modified, remain within the specifi-

cations of the PMA’s for the approved lenses. For this

reason, there is no basis for the argument that investiga-

tional lenses are subject to ‘‘eustom fitting,’’ while ap-

proved lenses are not. Further, the comments appear to

presuppose that the investigational lenses in question have

been shown to be safe and effective in the first place; the

comments do not add to the body of valid scientific evidence

that is required to estabilsh the safety and effectiveness of

the lenses proposed for reclassification. The comments,

therefore, are not relevant to the question of reclassifi-

cation.

21. More than 20 comments from investigators argue

that FDA should not regulate prescribing and fitting of

polyacrylate-silicone lenses by limiting reclassification to

spherical lens designs. According to these comments, pre-

scribing and fitting are best left to the experts in the prac-

tice of optometry and ophthalmology. These comments

64a

further argue that competition among laboratories that

make lens blanks into finished lenses and between fitters

or prescribers of lenses will rapidly force off the market

those members of each group who provide lenses that are

either uncomfortable or do not provide adequate visual

acuity. These comments also point out that FDA approval

of a contact lens does not prevent poor fitting or prescrib-

ing and claim that because the choice of designs in off-the-

shelf lenses is limited, the problem of poor fitting or pre-

scribing is exacerbated.

FDA limited the proposed rule to reclassify rigid gas

permeable lenses to spherical designs because of a com-

plete lack of valid scientific evidence of safety and effec-

tiveness of lenses of other than spherical designs. No such

evidence of the safety and effectiveness of lenses of other

than spherical designs was submitted during the comment

periods or at the public hearing on the proposal (see para-

graph 22 of this document). FDA recognizes that its ap-

proval.of a PMA for a contact lens will not prevent prac-

titioners from erring when fitting or prescribing the lens;

however, the inability of the agency to prevent such errors

in no way justifies the reclassification of a lens into class I

or class IT.

22. Several comments state that nonspherical lenses, in-

cluding toric, bitoric, and bifocal lenses, should have been

included in the proposed reclassification of rigid gas perme-

able lenses. The comments argue that any gas permeable

lens material that is suitable for spherical contact lenses

will be equally suitable for nonspherical lens designs. The

historical use of PMMA for lenses of both spherical and

nonspherical designs and the similarities of rigid gas

permeable materials to PMMA are cited in support of this

argument. Other comments argue that nonspherical rigid

gas permeable lenses were correctly excluded from the pro-

posed rule because there is insufficient valid scientific evi-

dence of the safety and effectiveness of such lenses for any

indication.

65a

Because FDA is withdrawing the proposed reclassifica-

tion of rigid gas permeable lenses, the question whether

nonspherical lens designs should have been included in the

proposal is moot. FDA advises, however, that spherical,

toric, bitoric, and bifocal lenses are indicated for different

ametropias and that there is no valid scient*fic evidence,

other than in PMA’s, that any nonsph ‘cal rigid gas

permeable lens is safe and effective for uny indication.

FDA recognizes that many characteristics of contact lenses

that affect safety are material-specific and that these char-

acteristics, e.g., toxicity and oxygen permeability, will not

be altered by changes from spherical to nonspherical lens

design. Other characteristics affecting effectiveness, as well

as safety, are functions of design and material in combina-

tion. Thus, for example, valid scientific evidence that spher-

ical and toric lenses made of the same material are safe

and effective for the correction of hyperopia, myopia, and

astigmatism do not constitute such evidence that a bifocal

lens that (1) ‘is also made of that material and (2) com-

bines design elements of the spherical and toric lenses is

effective or safe for the correction of presbyopia (see

United States v. Wesley-Jessen, Inc., Civil No. 82C874

(N.D. Il, March 11, 1982) (transcript of proceedings) ).

The machining and polishing characteristics and hence

the lens surface characteristics of rigid gas permeable

materials are not identical to those of PMMA, nor are

wetting characteristics, rigidity, or balance. Such differ-

ences may or may not result in differences in edema, stain-

ing, centration, orientation, and tear pumping characteris-

tics. Therefore, the safety and effectiveness of PMMA

lenses of spherical and nonspherical designs do not estab-

lish, by valid scientific evidence, the safety and effectiveness

of rigid gas permeable lenses of spherical or nonspherical

designs.

D. Adequacy of Characterization

23. One comment argues that characterization of rigid

gas permeable lenses by materials is adequate for the

66a

purpose of reclassification, citing the proposed rule to

classify PMMA contact lenses (47 FR 3746), and quoting

the preamble to the proposed rule to classify ophthalmic

devices (47 FR 3695): ‘‘The identification statement is

necessarily broad because it applies to a category or type

of device rather than to a specific device. * * * It is not

practical for FDA to publish an identification of each type

of device that is so detailed as to anticipate every product

feature that may be relevant in determining whether a new

device is substantially equivalent to previous devices

classified by the regulation.’’

As a general rule, characterization of a device by mate-

rial, at least in part, for the purpose of identifying the

generic type of device in a classification regulation is ap-

propriate. In the case of rigid gas permeable lenses, how-

ever, FDA has concluded that such characterization is not

feasible (see sections IT.B. and C. and paragraphs 13 and

24 of this document).

24. Several comments state that a lens defined as con-

sisting of a material described as polyacrylate-silicone can

include a broad range of characteristics and that this is

not a substantive definition. The comments note that pat-

ents based upon new composition of materials for the

manufacture of rigid gas permeable lenses reveal large

numbers of materials falling within the broad scope of

polyacrylate-silicone. The comments claim that these ma-

terials are unique beyond all prior art, prior art including

the polyacrylate-silicone material of the POLYCON® lens

evaluated in Refs. 30 and 31 of the proposal (also see para-

graphs 11 and 12 of this document). The comments argue

that it is neither reasonable nor scientifically valid to ex-

trapolate evidence of safety and effectiveness from lenses

of this one material, or any unique materials for which

data may be available, to lenses of other unique materials

within the general type of material, but for which data are

not available. The comments cite several references, in-

67a

cluding patents, that illustrate some of the changes in

characteristics that result from changes in formulation or

process. The comments conclude that whether a contact

lens made from a particular polyacrylate-silicone material

is safe and effective can be determined only by conducting

preclinical and clinical evaluations of the type identified

in FDA’s contact lens guideline. Consequently, the com-

ments state, evidence of the safety and effectiveness of a

specific lens of a particular polymer formulation and manu-

facturing process can only serve as evidence of the safety

and effectiveness of that lens. Such evidence fails to dem-

onstrate the safety and effectiveness of a generic type of

device.

FDA agrees with the comments. The term silicone acryl-

ate, even when limited by the definition in the preamble

to the proposed rule (47 FR 53406) : ‘‘ Polyacrylate-silicone

copolymer contact lenses consist of complex siloxany! meth-

acrylate polymers * * *. Such lenses contain PMMA for

rigidity and polymerized silicone for oxygen permeability’’,

or by the definition offered by the comments discussed in

paragraph 26 of this document, encompasses a virtually

infinite set of combinations of principal and adjunctive

ingredients. The number of such combinations suitable for

the manufacture of contact lenses, albeit perhaps finite, is

unknown, as is the range of variation of ingredient ratios,

polymerization processes, and resultant material charac-

teristics. (Much of this information may be known to manu-

facturers of contact lenses, but none of it was included in

or submitted with any of the comments, and FDA is pro-

hibited by sections 301(j) and 520(c) of the act from dis-

closing such information from PMA’s or files for investiga-

tional devices under development pursuant to IDE’s be-

cause such information constitutes trade secret data.)

As discussed in sections II.B. and C. and paragraphs 13

and 23 of this document, the existence of a predictable

relationship between a lens polymer formulation, manu-

68a

facturing process, physical and other quantifiable param-

eters, and its safety and effectiveness has not been demon-

strated by any valid scientific evidence. Lacking knowledge

of such a relationship one cannot infer from evidence that

any rigid gas permeable lens of unique polymer formula-

tion, produced by a unique process, and having unique

properties is safe and effective, that any other rigid gas

permeable lens also is safe and effective unless both lenses

are sufficiently characterized to demonstrate that they are

virtually identical.

Any effort to use the evidence of safety and effectiveness

of a specific rigid gas permeable lens or lenses as the basis

for reclassification of a generic type of lens, regardless of

how narrowly or broadly that generic type of lens is iden-

tified, requires detailed characterization of the lens or

lenses from which the evidence is drawn and the lenses to

which the characterization applies. This characterization

necessarily includes details of raw materials, polymer con-

stituents and ratios, and manufacturing information. With-

out such characterization there is no basis for extrapola-

tion of evidence of the safety and effectiveness from one

lens to any other.

E. Adequacy of General Controls

Several comments argue for and several comments argue

against the adequacy of class I to provide reasonable assnr-

ance of the safety and effectiveness of rigid gas permeable

lenses. These arguments center around the adequacy of

two principal provisions of the general controls, premarket

notification under section 510(k) of the act and enrrent

good manufacturing practice requirements under section

520(f) of the act and the current good manufacturing

practice (CGMP) regulations (21 CFR Part 820).

25. One comment argues that the premarket approval

process does not ensure safe and effective contact lenses or

their accessories. The comment cites examples of how the

69a

marketplace allegedly has exposed flaws in or led to im-

provements of lenses and lens accessories that had received

FDA approval, and concludes that introduction of new

daily-wear contact lenses by the premarket notification

process would be as safe as, and more efficient than, intro-

duction of such lenses under the premarket approval pro-

cess. The comment argues, therefore, that the lenses should

be reclassified into class I.

FDA disagrees with this comment. The legal standard

governing reclassification under section 513(e) of the act

is discussed in the preamble to the proposed rule (47 FR

53404) and in section I.A. of this document. FDA recog-

nizes that approval of a PMA for a contact lens or a

contact lens accessory does not always ensure that the

device will perform flawlessly in the marketplace. In addi-

tion, approval of a PMA does not protect or prevent a

device from being rapidly replaced by a new or improved

device as a result of needs expressed by consumers and

practitioners. This is especially true in the contact lens

industry, where the state-of-the-art is one of rapid and

continued innovation and refinement. Nonetheless, opinions

about the adequacy of premarket approval to ensure safe

and effective contact lenses cannot justify reclassification

and do not add to the body of valid scientific evidence that

is required to establish the safety and effectiveness of the

lenses proposed for reclassification.

26. Two comments provide a proposed definition of poly-

acrylate-silicone lens materials and a set of parameters

with assigned acceptance limits. The proposed definition

of polyacrylate-silicone reads: ‘‘copolymers composed

principally of simple alkyl acrylate or alkyl methacrvlate

monomers and silicone substituted acrylate or methacryl-

ate monomers. Additional components present in minor

proportions include the crosslinkers, wetting agents, stabil-

izers, and catalysts currently used to manufacture cross-

linked PMMA. The silicone-substituted acrylate or meth-

70a

acrylate monomer is further identified as an acryloxy or

methacryloxy alkyl or aryl substituted silicone. A silicone

is further defined as a polymeric chemical structure having

a backbone of alternating silicon and oxygen atoms.’’ The

set of parameters includes composition, luminous trans-

mittance, index of refraction, oxygen permeability, dimen-

sional stability, tensile strength, flexural strength, cyto-

toxicity, eye irritation, resistance to bacteria, extractables,

preservative uptake, wettability, and care system compati-

bility. The comments argue that polyacrylate-silicone lenses

whose material met the definition and all the parameters,

including certain preclinical testing requirements, would

be safe and effective, and that the set of parameters would

therefore be adequate to determine whether any new lens

was substantially equivalent to a reclassified lens. The com-

ments further argue that evidence of safety and effective-

ness need not include data and information on lens poly-

mer formulation or manufacturing process to provide an

adequate basis for reclassification because evaluation

against the parameters would screen out all unsafe and in-

effective lenses.

FDA disagrees with these comments. The definition pro-

vided in the comments describes a broad group of polymers

that could be accurately titled, ‘‘polyacrylate-silicone.’’ As

pointed out in one of the two comments, however, materials

meeting the definition suggested by the comments could

include any number of formulations that were either suit-

able or unsuitable for the manufacture of safe and effec-

tive contact lenses. The definition contains no provisions

to distingiush between suitable and unsuitable polyacrylate-

silicone materials, much less between safe and effective

and unsafe and ineffective lenses made from the materials.

Use of a set of parameters with assigned acceptance

limits without valid scientific evidence that lenses meeting

such limits would be safe and effective provides no assur-

ance of lens safety and effectiveness and is inadequate to

T7la

serve as a basis for determining substantial equivalence.

As stated in section I.E. and paragraph 34 of this dovnu-

ment, FDA is unaware of any combination of nonclinical

laboratory studies capable of predicting with reasonable

assurance the safety and effectiveness of any contact lens

on the human eye. In addition, neither comment contained,

and FDA is unaware of, any valid scientific evidence that a

lens meeting the parameters included in the comments, or

any other set of criteria, would be safe or effective, or that

use of the parameters included in the comments, or any

other set of criteria, would provide an adequate basis on

which to determine whether a new lens was substantially

equivalent to a reclassified lens in terms of safety and

effectiveness. Neither the parameters included in the com-

ments nor any other set of criteria could serve as a basis

for reclassification unless they were supported by valid

scientific evidence showing that their use in determination

of substantial equivalence would provide reasonable assur-

ance of the safety and effectiveness of the new lens as

compared to the reclassified lens. As discussed in sections

II.B. and C. and paragraphs 13, 23, and 24 of this docu-

ment, lacking such evidence, information characterizing

lenses by polymer formulation and manufacturing pro-

cesses is essential to any evidence of safety and effective-

ness that could serve as a basis for reclassification, and

would be essential to determine substantial equivalence of

any new lens in the event that any rigid gas permeable

lens were reclassified.

27. Several comments object to the statement in the pre-

amble to the proposal concerning the information that

FDA would require to be included in a premarket notifica-

tion submission under section 510(k) of the act for a con-

tact lens. The comments argue that requiring all this in-

formation would exceed FDA’s authority under section

510(k) of the act and would amount to a ‘‘mini-premarket

approval’’ requirement.

72a

FDA agrees in part with these comments. In the pre-

amble to the proposal, FDA stated that the manufacturer

of a contact lens should be prepared to demonstrate sub-

stantial equivalence in terms including but not limited to,

design ; composition ; optical transmission and homogeneity,

and index of refraction; and other physical properties in-

cluding oxygen permeability, chemical and physical stability,

tensile and flexural strength; biocompatibility, including

cytoxicity, eye irritation and nonsupport of bacterial

growth; impurities; leachables; heavy metal levels; pre-

servative uptake and release; and lens care/cleaning regi-

men compatibility as well as compliance with the CGMP

regulations. All this information concerns the basic char-

acteristics of contact lenses. If FDA had reclassified the

lenses, such information would have been needed by FDA

in a premarket notification submission to determine

whether a new contact lens was substantially equivalent

to a reclassified lens in terms of safety and effectiveness.

Section 807.87(h) of the regulations governing premarket

notification procedures provides that FDA may require

the submission of any information that is necessary for

FDA to determine whether a device is substantially equiva-

lent in terms of safety and effectiveness to a preamend-

ments device or to a transitional or postamendments de-

vice reclassified into class I or class IT. For a contact lens,

this information may include any or all of the information

cited above, and may also include, where necessary to

determine comparability of safety and effectiveness, lim-

ited data from nonclinical laboratory studies and clinical

investigations.

As diseussed in sections IT.C. and E. and paragraphs 13

and 34 of this document, extensive data from studies and

investigations are necessary to provide reasonable assur-

ance of the safety and effectiveness of rigid gas permeable

lenses. FDA recognizes that requiring such much informa-

tion would result in the submission of data so complete

73a

as to be indistinguishable from the data needed to deter-

mine the safety and effectiveness of a device in the first

instance rather than on a comparison basis. The data

required in a premarket notification submission would

then be indistinguishable from the data required in a PMA.

FDA agrees that imposing such a requirement as an a

priors condition for determining substantial equivalence

would exceed the authority of section 510(k) of the act

and Subpart E of Part 807. If such extensive submissions

would be necessary to determine substantial equivalence

in terms of safety and effectiveness of the device, it follows

that class I controls would be inadequate to provide reason-

able assurance of safety and effectiveness of the device.

28. One comment argues that if the testing of lenses

that is necessary to show that a lens is substantially equiv-

alent to a reclassified lens approximates that which would

be necessary for a premarket approval application, ‘‘such

expansion of the 510(k) concept would not be justified.’’

FDA agrees with the comment. Where, as in this case,

the type and amount of information that would be required

to show substantial equivalence in terms of safety and

effectiveness would approximate the type and amount of

information required to obtain approval of a PMA for a

device, reclassification of the device based on reliance on

the process under section 510(k) of the act would not be

justified.

29. One comment argues that if FDA requires lenses of

new materials to be virtually identical to lenses of re-

classified materials, it will be impossible to market alter-

nate contact lens materials under section 510(k) of the act.

The comment claims that such an interpretation of the

substantial equivalence requirement would hinder the

marketing of improved rigid gas permeable materials.

FDA agrees that if it had reclassified any of the lenses

proposed for reclassification and required that any new

74a

lens be virtually identical to a reclassified lens, it would

not have been possible to market under section 510(k) of

the act lenses made of alternate materials. Whether such

a requirement would have hindered the marketing of ‘‘im-

proved’”’ rigid gas permeable lenses is unknown. FDA

advises, however, that any postamendments device, includ-

ing any contact lens, that is not substantially equivalent

to a preamendments device or a postamendments device

that has been reclassified is automatically classified into

class III under section 513(f) of the act and cannot legally

be marketed unless it is the subject of an approved PMA

or has been reclassified.

30. One comment states that all CAB and polyacrylate-

silicone materials that are ‘‘equally suitable for their in-

tended use, as compared to already approved lens mate-

rials, should be recognized as substantially equivalent to

those materials * * * ’’.

FDA disagrees with the comment. The act applies to

devices as defined in section 201(h) of the act (21 U.S.C.

321(h)), rather than raw materials. If, however, the act

applied to raw materials, any postamendments raw mate-

rial, including any contact lens raw material, that was not

substantially equivalent to a preamendments raw material

or a postamendments raw material that had been reclassi-

fied would be automatically classified into class IIT under

section 513(f) of the act and could not legally be marketed

unless it were the subject of an approved PMA or had

been reclassified. FDA notes that the comment provides

no definition of the concept of ‘‘equal suitability.’’

31. Several comments state that enforcement of the

CGMP regulations is essential to ensure adequate quality

control of contact lens manufacture and to prevent the

distribution of unsafe or ineffective lenses. Some of these

comments point out that according to the preamble to the

proposed rule (47 FR 53405), manufacturers would be

required to demonstrate compliance with the CGMP regn-

75a

lations to establish substantial equivalence. Some of these

comments argue that to ensure such compliance, FDA

would have to inspect the manufacturing sites identified in

premarket notification submissions and that such inspec-

tions could not be scheduled and completed in the 90 days

allowed for review by FDA of such submissions. In such

case, the comments note, the person submitting the pre-

market notification could market lenses without an inspec-

tion by FDA of the person’s manufacturing facility. Some

of these comments also note that FDA has no requirements

for mandatory CGMP inspections of facilities in which

class I devices are manufactured and that the lack of such

regular inspections could result in the marketing of unsafe

or ineffective contact lenses, if the lenses were reclassified

into class I.

FDA agrees that compliance with the CGMP regulations

is essential to ensure the manufacture of safe and effective

contact lenses because of the need for consistency in formu-

lating, processing, and finishing these devices. Because

FDA is withdrawing the proposed rule, the question

whether FDA may require the inclusion in a premarket

notification submission of sufficient information to deter-

mine whether a manufacturer’s facility is in compliance

with the CGMP regulations as part of the premarket notifi-

cation review is moot. FDA, of course, has the authority to

conduct CGMP inspections of any device establishment,

including any device manufacturing facility, regardless of

the classification of a device, to determine whether the

facility is in compliance with the regulations.

F. Adequacy of Class II

32. Several comments, including those that responded

explicitly to questions 1.d. and e. of the preamble to the

proposed rule, argue that class II would be the most ap-

propriate regulatory class for rigid gas permeable lenses.

Most of these comments also argue that any reclassification

76a

of rigid gas permeable lenses into class II should not take

effect before a perf-- ce standard under section 514 of

the act is establish ach lenses. Some comments argue

that there is, while ochers argue that there is not, sufficient

valid scientific evidence to establish such a standard. A

number of comments state that a performance standard

covering lens properties or design characteristics, such as

the clinically significant properties and design character-

istics cited in the preamble to the proposed rule (47 FR

53405), would be sufficient to provide reasonable assurance

of safety and effectiveness of the lenses. Several other com-

ments argue that any such standard needs to include a re-

quirement for clinical investigation of the lenses.

FDA stated in the preamble to the proposed rule (47 FR

53405) :

This proposal to reclassify daily wear spherical con-

tact lenses composed of CAB or polyacrylate-silicone

into class I, rather than into class IT upon the effective

date of a performance standard promulgated in accord-

ance with section 514 of the act, is based on FDA’s

tentative conclusion that general controls are sufficient

to provide reasonable assurance of the safety and

effectiveness of such lenses. FDA believes that suffi-

cient information exists to establish a section 514

standard to provide reasonable assurance of the safety

and effectiveness of the device; however, FDA does

not believe it is necessary to establish such a standard

to provide such assurance.

FDA has determined that its tentative conclusion about

the adequacy of general controls was in error and that

sufficient information does not exist to establish a perform-

ance standard under section 514 of the act. The requirement

that reclassification of a device be based on valid scientific

evidence of safety and effectiveness applies to reclassifica-

tion from class ITT into class IT, as well as to reclassifica-

77a

tion from class ITI into class I. As discussed in sections

IL.B. and IT.C. of this document, FDA has concluded that

there is insufficient valid scientific evidence other than in

PMA’s to show that rigid gas permeable lenses are safe

and effective. For this reason, FDA cannot conclude that

such lenses should not remain in class III, or determine

whether reclassification into class [T, as opposed to class I,

» Would provide reasonavie assurance of their safetv and

effectiveness. Furthermore, any performance standard that

addressed and set parametric limits on lens properties or

’, design characteristics, such as the clinically significant

properties and design characteristics cited in the preamble

to the proposed rule, the set of parameters listed and dis-

cussed in section IT.D. and paragraph 26 of this document,

or the material properties delineated in ANSI Z80.6-1983

(see paragraph 33 of this document) would have to be

based on valid scientific evidence that the standard would

provide reasonable assurance of the safety and effective-

ness of the lenses covered by the standard. As discussed

in section IT.D. and paragraphs 26 and 32 of this docu-

ment, FDA has concluded that no such evidence is publicly

available. Absent sufficient information to establish a per-

formance standard to provide reasonable assurance of the

safety and effectiveness of a device, the device mey not be

reclassified into class IT, because under section 513(a)(1)

(B) of the act, a class IT device is a device for which,

among other things, ‘‘there is sufficient information to

establish a performance standard to provide’’ reasonable

assurance of safety and effectiveness.

FDA believes that in lieu of a standard under section

514 of the act prescribing performance criteria, a standard

under that section prescribing testing and evaluation cri-

teria to provide reasonable assurance of the safetv and

effectiveness of rigid gas permeable lenses might be feasi-

ble. At this time, however, such a standard could not be

developed based on information available in the public

domain. FDA notes that if there were sufficient valid scien-

iia iii

78a

tific evidence to develop a testing and evaluation standard,

its existence would serve as a principle part of the basis

for the reclassification into class II of any rigid gas perme-

able lens to be covered by the standard. Consequently, any

resulting reclassification could not become effective prior

to the effective date of such standard.

33. A few comments suggest that a voluntary standard

(ANSI Z80.6-1983) titled, ‘‘American National Standard

for Ophthalmics—Conventional Hard Plastic Contact

Lenses—Physiochemical Properties,’’ published by the

American National Standards Institute, Inc. (ANSI) could

serve as the basis for the establishment of a performance

standard under section 514 of the act in the event that FDA

decided to reclassify rigid gas permeable lenses into class

II rather than class I. Some of these comments argue that

the existence of ANSI Z80.6-1983 is adequate evidence that

there is sufficient information to develop a performance

standard. One comment submitted a copy of ANSI Z80.6-

1983 to the record.

No comments submitted, and FDA is unaware of, any

evidence that a lens made of a material that meets ANSI

Z80.6-1983 is safe and effective. While it may be feasible

to show, through a series of measurements of approved

rigid gas permeable lenses, that all such lenses meet the

subject standard, there is no basis to conclude that any

other lens that meets the standard would necessarily be

either safe or effective. Quite the contrary, ANSI Z80.6-

1983 addresses only a limited number of physiochemical

properties of contact lens materials. Adherence to the vol-

untary standard would not ensure that lenses made from

materials meeting the standard would be nontoxic, bio-

compatible, or effective.

G. Need for Clinical Trials

34. Several comments state that clinical trials are neces-

sary to provide reasonable assurance of the safety and

79a

effectiveness of rigid gas permeable lenses. Some of the

comments state that if such lenses were reclassified, at

least limited clinical trials would be necessary to establish

the safety and effectiveneds of lenses made of a new or

modified material or lenses made by a new manufacturer.

The comments argue that differences in lens polymer

formulation, changes in manufacturing process or process

control, or changes from one manufacturer to another can

result in changes in lens’ clinical performance that can

only be adequately evaluated in a clinical trial. Two com-

ments argue, on the contrary, that lenses meeting a defini-

tion of polyacrylate-silicone provided in the comments, and

a set of parameters with assigned acceptance limits, also

provided in the comments, would be safe and effective and

therefore would not need clinical evaluation. Another com-

ment states that the persons who claim that clinical trials

are necessary to provide reasonable assurance of the safety

and effectiveness of rigid gas permeable lenses have failed

to provide any valid scientific evidence that such trials are

necessary.

Each of these comments and related arguments are sum-

marized and addressed in sections II.C. and E. and para-

graphs 13, 22, 24, and 26 of this document. PDA has regu-

lated contact lenses as new drugs or class III devices for

more than a decade, and is unaware of any combination of

nonclinical laboratory studies capable of predicting the

performance of any contact lens on the human eye. Nothing

in the comments that provided the definition and the set

of parameters, or in any other comments, establishes that

clinical trials are not necessary to provide reasonable as-

surance of the safety and effectiveness of polyacrylate-sili-

cone lenses, or that polyacryiate-silicone lenses whose ma-

terial met the definition and the parameters would be safe

and effective.

As stated in section IT.E. of this document, FDA believes

that the safety and effectiveness of a contact lens is a

80a

function of the complex interrelationship of material, de-

sign, and manufacture that results in a unique set of physi-

cal, chemical, mechanical, and optical characteristics. When

prescribed and fitted properly, a lens with this unique set

of characteristics should provide safe and effective visual

correction in a human eye with a specific diagnosed ame-

tropia. FDA believes that contact lenses made from a new

material, including material that has been significantly

modified, contact lenses made to significantly modified de-

signs, and contact lenses for which approval for a new

indication is sought, cannot at this time be shown to be

safe and effective without clinical, as well as preclinical,

evaluation.

FDA agrees that none of the comments provided any

valid scientific evidence that clinical trials are necessary

to provide reasonable assurance of the safety and effective-

ness of rigid gas permeable lenses. As explained in para-

graph 4 of this document, however, the burden of proof in

this proceeding requires FDA (or the proponents of re-

classification) to establish, by valid scientific evidence of .

safety and effectiveness, that rigid gas permeable lenses

should not remain in class III and that class I (or class

II) would provide reasonable assurance of the safety and

effectiveness of such lenses. The opponents of reclassifica-

tion are not required to provide any evidence to establish

that reclassification is inappropriate.

H. Economic impact of Reclassification

35. Many comments support reclassification from class

III into class I on economic grounds.

FDA notes that only a few of the comments contain any

economic data to support their claims, and that none of

these data was substantiated by accompanying documen-

tation. In any event, even if the claims were substantiated,

FDA could not have legally reclassified any rigid gas

permeable lens, nor could the agency legally reclassify any

8la

other class III device into class I or class II, absent the

requisite valid scientific evidence of safety and effective-

ness (see the preamble to the proposed rule (47 FR 53404)

and section I.A. of this document).

36. Many comments cite the current classification of

rigid gas permeable lenses as ‘‘a completely unnecessary

barrrier to competition’’ that threatens the viability and

welfare of small businesses. The comments, citing recent

poor business and layoffs, attribute the hardship of the

small contact lens manufacturer to the current classifi-

cation.

As explained in paragraph 1 of this document, all rigid

gas permeable lenses are class III devices as a result of,

among other things, (1) the September 30, 1975 notice and

(2) section 520(1)(1)(E) and (1)(3)(D)(i) of the act. The

1975 notice was based on concerns about the safety and

effectiveness of lenses consisting of polymers other than

“PMMA see paragraph 19 of this document). These con-

cerns continue to justify classification of such lenses into

class ITI, as discussed more fully in section II.B. and para-

graphs 13, 23, 24, and 26 of this document. Thus. classifi-

cation into class III is not ‘‘unnecessary.’’ Furthermore,

a number of small companies hold approved PMA’s for

non-PMMA lenses, including rigid gas permeable lenses.

FDA notes that approved PMA’s for several polyacrylate-

silicone lenses cover a total of more than 250 contact lens

finishing laboratories, and that the agency has advised each

of the PMA holders how more such laboratories can be

approved as additional manufacturing sites without the

need for the PMA holders or the laboratories to gather

additional clinical data. FDA has received no evidence of

the cause of the poor business and resultant layoffs cited

in the comments.

37. Several comments complain of the ‘‘de facto monop-

oly’’ held by large manufacturers that hold approved

PMA’s. One of these comments complained that the re-

82a

quirements associated with securing premarket approval

cost ‘‘in the neighborhood of $1 million.’’

FDA does not agree with the comments. Small companies

can and do obtain approved PMA’s. Although the figure

of $1 million is unsubstantiated, FDA is aware that the

requirements for premarket approval are stringent and as

discussed in paragraph 36 of this document, has taken

steps to make the premarket approval process less burden-

some for the contact lens industry. The agency advises,

however, that Congress chose to protect the data in PMA’s

from use by others seeking premarket approval and from

use by others and by FDA for the purpose of reclassifica-

tion (see the preamble to the proposed rule (47 FR 53404)

and section IT.A. of this document).

38. One comment claims that although the cost of rigid

gas permeable lenses would decline as

This text is long and has been trimmed here. Open the source document for the complete record.

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.